0001630113 2021-04-01 2021-06-30 0001630113 2021-08-16 0001630113 2021-06-30 0001630113 2021-03-31 0001630113 us-gaap:SeriesAPreferredStockMember 2021-06-30 0001630113 us-gaap:SeriesAPreferredStockMember 2021-03-31 0001630113 2020-04-01 2020-06-30 0001630113 us-gaap:PreferredStockMember 2021-03-31 0001630113 us-gaap:CommonStockMember 2021-03-31 0001630113 BTCY:SharesToBeIssuedMember 2021-03-31 0001630113 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001630113 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0001630113 us-gaap:RetainedEarningsMember 2021-03-31 0001630113 us-gaap:PreferredStockMember 2021-04-01 2021-06-30 0001630113 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0001630113 BTCY:SharesToBeIssuedMember 2021-04-01 2021-06-30 0001630113 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0001630113 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-04-01 2021-06-30 0001630113 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0001630113 us-gaap:PreferredStockMember 2021-06-30 0001630113 us-gaap:CommonStockMember 2021-06-30 0001630113 BTCY:SharesToBeIssuedMember 2021-06-30 0001630113 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001630113 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-06-30 0001630113 us-gaap:RetainedEarningsMember 2021-06-30 0001630113 us-gaap:PreferredStockMember 2020-03-31 0001630113 us-gaap:CommonStockMember 2020-03-31 0001630113 BTCY:SharesToBeIssuedMember 2020-03-31 0001630113 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001630113 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0001630113 us-gaap:RetainedEarningsMember 2020-03-31 0001630113 2020-03-31 0001630113 us-gaap:PreferredStockMember 2020-04-01 2020-06-30 0001630113 us-gaap:CommonStockMember 2020-04-01 2020-06-30 0001630113 BTCY:SharesToBeIssuedMember 2020-04-01 2020-06-30 0001630113 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-06-30 0001630113 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-04-01 2020-06-30 0001630113 us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0001630113 us-gaap:PreferredStockMember 2020-06-30 0001630113 us-gaap:CommonStockMember 2020-06-30 0001630113 BTCY:SharesToBeIssuedMember 2020-06-30 0001630113 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001630113 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-06-30 0001630113 us-gaap:RetainedEarningsMember 2020-06-30 0001630113 2020-06-30 0001630113 2021-01-01 2021-03-31 0001630113 2021-01-01 2021-06-30 0001630113 BTCY:EconomicInjuryDisasterLoanMember 2021-04-01 2021-06-30 0001630113 BTCY:PromissoryNoteAndOtherNetShortTermFundingMember 2021-04-01 2021-06-30 0001630113 BTCY:PromissoryNoteMember 2021-03-31 0001630113 srt:MinimumMember BTCY:PromissoryNoteMember 2021-03-31 0001630113 srt:MaximumMember BTCY:PromissoryNoteMember 2021-03-31 0001630113 BTCY:PromissoryNoteMember 2020-04-01 2021-03-31 0001630113 BTCY:NoteHolderOneMember 2020-04-01 2021-03-31 0001630113 BTCY:NoteHolderOneMember us-gaap:SeriesAPreferredStockMember 2020-04-01 2021-03-31 0001630113 BTCY:NoteHolderOneMember us-gaap:SeriesAPreferredStockMember 2021-03-31 0001630113 BTCY:PromissoryNoteMember 2021-06-30 0001630113 BTCY:ShortTermLoanMember 2021-06-30 0001630113 BTCY:ShortTermLoanMember 2021-03-31 0001630113 us-gaap:InterestExpenseMember 2020-04-01 2021-03-31 0001630113 BTCY:GeneralAndAdministrativeExpensesMember 2020-04-01 2020-06-30 0001630113 BTCY:SeriesANotesMember 2020-04-01 2021-03-31 0001630113 BTCY:SeriesANotesMember 2021-03-31 0001630113 BTCY:SeriesANotesMember 2021-04-01 2021-06-30 0001630113 BTCY:SeriesBNotesMember 2021-03-31 0001630113 BTCY:SecondSeriesANotesMember 2020-04-01 2021-03-31 0001630113 2020-04-01 2021-03-31 0001630113 BTCY:SeriesBNotesMember us-gaap:WarrantMember 2021-03-31 0001630113 BTCY:PlacementAgentMember BTCY:SeriesANotesMember 2020-04-01 2021-03-31 0001630113 2021-01-08 0001630113 BTCY:SeriesBNotesMember 2021-06-30 0001630113 BTCY:SeriesANotesMember 2021-06-30 0001630113 BTCY:SeriesANotesMember 2021-07-01 2021-09-30 0001630113 BTCY:SeriesBNotesMember 2020-04-01 2021-03-31 0001630113 BTCY:ConversionNoticeMember 2020-04-01 2021-03-31 0001630113 BTCY:SeriesBNotesMember BTCY:WarrantOneMember 2021-03-31 0001630113 BTCY:SeriesBNotesMember 2021-04-01 2021-06-30 0001630113 us-gaap:InterestExpenseMember 2021-04-01 2021-06-30 0001630113 BTCY:CaptionedProgramMember BTCY:USSmallBusinessAdministrationMember 2020-04-01 2020-04-30 0001630113 BTCY:CaptionedProgramMember BTCY:USSmallBusinessAdministrationMember 2020-04-30 0001630113 BTCY:USSmallBusinessAdministrationMember 2021-05-31 0001630113 BTCY:PaymentProtectionProgramMember 2020-05-01 2020-05-31 0001630113 us-gaap:SeriesAPreferredStockMember 2020-01-09 0001630113 us-gaap:SeriesAPreferredStockMember 2021-04-01 2021-06-30 0001630113 us-gaap:SeriesAPreferredStockMember 2019-12-19 2020-01-09 0001630113 BTCY:PromissoryNotesMember 2019-12-19 2020-01-09 0001630113 us-gaap:SeriesAPreferredStockMember 2020-05-22 0001630113 us-gaap:SeriesAPreferredStockMember 2020-05-21 2020-05-22 0001630113 us-gaap:MeasurementInputExpectedDividendRateMember 2021-06-30 0001630113 srt:MinimumMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2021-06-30 0001630113 srt:MaximumMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2021-06-30 0001630113 srt:MinimumMember us-gaap:MeasurementInputPriceVolatilityMember 2021-06-30 0001630113 srt:MaximumMember us-gaap:MeasurementInputPriceVolatilityMember 2021-06-30 0001630113 srt:MinimumMember us-gaap:MeasurementInputExpectedTermMember 2021-04-01 2021-06-30 0001630113 srt:MaximumMember us-gaap:MeasurementInputExpectedTermMember 2021-04-01 2021-06-30 0001630113 srt:MinimumMember 2021-06-30 0001630113 srt:MaximumMember 2021-06-30 0001630113 us-gaap:ConvertibleDebtMember 2021-04-01 2021-06-30 0001630113 BTCY:SeriesANoteMember us-gaap:ConvertibleDebtMember 2020-04-01 2021-03-31 0001630113 BTCY:SeriesBNoteMember us-gaap:ConvertibleDebtMember 2020-04-01 2021-03-31 0001630113 us-gaap:ConvertibleDebtMember 2020-04-01 2021-03-31 0001630113 us-gaap:ConvertibleDebtMember 2021-03-31 0001630113 us-gaap:ConvertibleDebtMember 2021-06-30 0001630113 srt:MinimumMember BTCY:ConversionAndRedemptionFeaturesMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2021-06-30 0001630113 srt:MaximumMember BTCY:ConversionAndRedemptionFeaturesMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2021-06-30 0001630113 srt:MinimumMember BTCY:ConversionAndRedemptionFeaturesMember us-gaap:MeasurementInputPriceVolatilityMember 2021-06-30 0001630113 srt:MaximumMember BTCY:ConversionAndRedemptionFeaturesMember us-gaap:MeasurementInputPriceVolatilityMember 2021-06-30 0001630113 srt:MinimumMember BTCY:ConversionAndRedemptionFeaturesMember us-gaap:MeasurementInputExpectedTermMember 2021-04-01 2021-06-30 0001630113 srt:MaximumMember BTCY:ConversionAndRedemptionFeaturesMember us-gaap:MeasurementInputExpectedTermMember 2021-04-01 2021-06-30 0001630113 srt:MinimumMember BTCY:ConversionAndRedemptionFeaturesMember 2021-06-30 0001630113 srt:MaximumMember BTCY:ConversionAndRedemptionFeaturesMember 2021-06-30 0001630113 us-gaap:SeriesAPreferredStockMember 2020-03-31 0001630113 BTCY:ShareholdersMember BTCY:ExchangeAgreementMember 2021-04-01 2021-06-30 0001630113 BTCY:ShareholdersMember BTCY:ExchangeAgreementMember 2020-04-01 2021-03-31 0001630113 BTCY:ExchangecoMember BTCY:ExchangeAgreementMember 2021-04-01 2021-06-30 0001630113 BTCY:OptionsMember BTCY:ExchangeAgreementMember 2021-04-01 2021-06-30 0001630113 us-gaap:WarrantMember BTCY:ExchangeAgreementMember 2021-04-01 2021-06-30 0001630113 BTCY:AdvisorWarrantMember BTCY:ExchangeAgreementMember 2020-04-01 2021-03-31 0001630113 BTCY:ElevenPercentageSecuredConvertiblePromissoryNotesMember BTCY:ExchangeAgreementMember 2021-04-01 2021-06-30 0001630113 us-gaap:SeriesAPreferredStockMember 2020-04-01 2021-03-30 0001630113 us-gaap:SeriesAPreferredStockMember 2019-04-01 2020-03-30 0001630113 2020-04-01 2021-03-30 0001630113 BTCY:IssuanceOfCommonSharesMember BTCY:AdvisorMember 2020-04-01 2021-03-31 0001630113 BTCY:ConvertibleNotesMember 2021-03-31 0001630113 BTCY:ConvertibleNotesMember 2020-04-01 2021-03-31 0001630113 BTCY:ConvertibleNotesMember us-gaap:CommonStockMember 2020-04-01 2021-03-31 0001630113 BTCY:IssuanceOfCommonSharesMember BTCY:AdvisorMember 2021-04-01 2021-06-30 0001630113 BTCY:ConvertibleNotesMember 2021-06-30 0001630113 BTCY:ConvertibleNotesMember 2021-04-01 2021-06-30 0001630113 BTCY:ConvertibleNotesMember us-gaap:CommonStockMember 2021-04-01 2021-06-30 0001630113 us-gaap:WarrantMember 2021-03-31 0001630113 BTCY:AdvisorAndConsultantTwoMember us-gaap:WarrantMember 2020-04-01 2021-03-31 0001630113 srt:ChiefFinancialOfficerMember us-gaap:WarrantMember 2020-04-01 2021-03-31 0001630113 srt:MinimumMember BTCY:AdvisorAndConsultantTwoMember us-gaap:WarrantMember 2019-04-01 2020-03-31 0001630113 srt:MaximumMember BTCY:AdvisorAndConsultantTwoMember us-gaap:WarrantMember 2019-04-01 2020-03-31 0001630113 srt:ChiefFinancialOfficerMember us-gaap:WarrantMember 2019-04-01 2020-03-31 0001630113 BTCY:BrokersMember us-gaap:WarrantMember 2021-03-31 0001630113 BTCY:ConvertibleNoteholdersMember us-gaap:WarrantMember 2021-03-31 0001630113 BTCY:AdvisorAndConsultantTwoMember us-gaap:WarrantMember 2021-04-01 2021-06-30 0001630113 BTCY:AdvisorAndConsultantTwoMember BTCY:ConvertibleNotesMember us-gaap:WarrantMember 2021-06-30 0001630113 BTCY:AdvisorAndConsultantTwoMember BTCY:ConvertibleNotesMember us-gaap:WarrantMember 2021-04-01 2021-06-30 0001630113 BTCY:OneWarrantHolderMember 2021-04-01 2021-06-30 0001630113 BTCY:OneWarrantHolderMember 2021-06-30 0001630113 BTCY:OneWarrantHolderMember 2021-06-30 0001630113 BTCY:BrokerWarrantsMember 2020-03-31 0001630113 BTCY:ConsultantWarrantsMember 2020-03-31 0001630113 BTCY:WarrantsIssuedOnConversionOfConvertibleNotesMember 2020-03-31 0001630113 BTCY:PrivatePlacementWarrantsMember 2020-03-31 0001630113 BTCY:BrokerWarrantsMember 2020-04-01 2021-03-31 0001630113 BTCY:ConsultantWarrantsMember 2020-04-01 2021-03-31 0001630113 BTCY:WarrantsIssuedOnConversionOfConvertibleNotesMember 2020-04-01 2021-03-31 0001630113 BTCY:PrivatePlacementWarrantsMember 2020-04-01 2021-03-31 0001630113 BTCY:BrokerWarrantsMember 2021-03-31 0001630113 BTCY:ConsultantWarrantsMember 2021-03-31 0001630113 BTCY:WarrantsIssuedOnConversionOfConvertibleNotesMember 2021-03-31 0001630113 BTCY:PrivatePlacementWarrantsMember 2021-03-31 0001630113 BTCY:BrokerWarrantsMember 2021-04-01 2021-06-30 0001630113 BTCY:ConsultantWarrantsMember 2021-04-01 2021-06-30 0001630113 BTCY:WarrantsIssuedOnConversionOfConvertibleNotesMember 2021-04-01 2021-06-30 0001630113 BTCY:PrivatePlacementWarrantsMember 2021-04-01 2021-06-30 0001630113 BTCY:BrokerWarrantsMember 2021-06-30 0001630113 BTCY:ConsultantWarrantsMember 2021-06-30 0001630113 BTCY:WarrantsIssuedOnConversionOfConvertibleNotesMember 2021-06-30 0001630113 BTCY:PrivatePlacementWarrantsMember 2021-06-30 0001630113 srt:MinimumMember BTCY:BrokerWarrantsMember 2021-06-30 0001630113 srt:MaximumMember BTCY:BrokerWarrantsMember 2021-06-30 0001630113 srt:MinimumMember BTCY:ConsultantWarrantsMember 2021-06-30 0001630113 srt:MaximumMember BTCY:ConsultantWarrantsMember 2021-06-30 0001630113 srt:MinimumMember BTCY:WarrantsIssuedOnConversionOfConvertibleNoteMember 2021-06-30 0001630113 srt:MaximumMember BTCY:WarrantsIssuedOnConversionOfConvertibleNoteMember 2021-06-30 0001630113 BTCY:WarrantsIssuedOnConversionOfConvertibleNoteMember 2021-04-01 2021-06-30 0001630113 BTCY:TwoThousandAndSixteenEquityIncentivePlanMember 2016-01-30 2016-02-02 0001630113 BTCY:TwoThousandAndSixteenEquityIncentivePlanMember 2016-02-02 0001630113 BTCY:BoardOfDirectorMember BTCY:TwoThousandAndSixteenEquityIncentivePlanMember 2019-04-01 2020-03-31 0001630113 srt:MinimumMember BTCY:TwoThousandAndSixteenEquityIncentivePlanMember 2020-03-01 2020-03-31 0001630113 srt:MaximumMember BTCY:TwoThousandAndSixteenEquityIncentivePlanMember 2020-03-01 2020-03-31 0001630113 BTCY:TwoThousandAndSixteenEquityIncentivePlanMember 2020-03-31 0001630113 BTCY:TwoThousandAndSixteenEquityIncentivePlanMember 2020-04-01 2021-03-31 0001630113 BTCY:TwoThousandAndSixteenEquityIncentivePlanMember 2019-04-01 2020-03-31 0001630113 BTCY:TwoThousandAndSixteenEquityIncentivePlanMember 2021-04-01 2021-06-30 0001630113 us-gaap:GeneralAndAdministrativeExpenseMember BTCY:TwoThousandAndSixteenEquityIncentivePlanMember 2021-06-30 0001630113 2017-03-31 0001630113 2017-04-01 2018-03-31 0001630113 2018-03-31 0001630113 2018-04-01 2019-03-31 0001630113 2019-03-31 0001630113 2019-04-01 2020-03-31 0001630113 srt:MinimumMember 2021-03-31 0001630113 srt:MaximumMember 2021-03-31 0001630113 srt:MinimumMember 2020-03-31 0001630113 srt:MaximumMember 2020-03-31 0001630113 srt:MinimumMember 2019-03-31 0001630113 srt:MaximumMember 2019-03-31 0001630113 srt:MinimumMember 2021-04-01 2021-06-30 0001630113 srt:MaximumMember 2021-04-01 2021-06-30 0001630113 srt:MinimumMember 2020-04-01 2021-03-31 0001630113 srt:MaximumMember 2020-04-01 2021-03-31 0001630113 srt:MinimumMember 2019-04-01 2020-03-31 0001630113 srt:MaximumMember 2019-04-01 2020-03-31 0001630113 srt:MinimumMember 2018-04-01 2019-03-31 0001630113 srt:MaximumMember 2018-04-01 2019-03-31 0001630113 2019-04-02 0001630113 us-gaap:AccountingStandardsUpdate201902Member 2021-03-31 0001630113 us-gaap:AccountingStandardsUpdate201902Member 2021-04-01 2021-06-30 0001630113 us-gaap:AccountingStandardsUpdate201902Member 2021-06-30 0001630113 2021-06-01 2021-06-30 0001630113 us-gaap:SubsequentEventMember 2021-07-01 2021-07-02 0001630113 us-gaap:SubsequentEventMember 2021-07-01 2021-08-16 0001630113 us-gaap:SubsequentEventMember 2021-08-16 0001630113 BTCY:InvestorsMember us-gaap:SubsequentEventMember 2021-07-01 2021-07-02 0001630113 BTCY:BrokersMember us-gaap:SubsequentEventMember 2021-07-01 2021-07-02 iso4217:USD shares iso4217:USD shares pure 0001630113 true --03-31 2022 Q1

10-Q/A Amendment No. 1 true 2021-06-30 false 000-56074 BIOTRICITY INC. NV 30-0983531 275 Shoreline Drive Suite 150 Redwood City CA 94065 (650) 832-1626 Yes Yes Non-accelerated Filer true false false 40687578

201588

2201562

1950333

1520836

179799

272493

412885

326664

2744605

4321555

22679 50358

66120

2767284

4438033

2960953

2520124

5595465

4278018

3733256

3633856

58257

12289674

10490255

870800 370900

206517

410042

13366991

11271197

0.001

10000000

0.001

20000

8045

0.001

125000000

37850064

36124964

1466718

2889978

39317

39015

651169 268402 1511462 280960

57192182

56298726

-627626

-634186

-68715051

-62817688

-10599707

-6833164

2767284

4438033

1764110

451898

525426

201342

1238684

250556

3652203

3195353

588997

423883

4241200

3619236

19433

-7359

2335167

-298983

204142

-5656099

-3157179

-5656099

-3157179

241264

237215

-5897363

-3394394

6560

-105001

-5890803

-3499395

-0.151

-0.092

39095637

36768299

8046

39014942

39015

268402

280960

56298726

-634186

-62817688

-6833164

201604

202

327274

1190502

479558

1670262

100236 100 37736 40000 106150 146250 151897 151897

155851

6560

-5656099

241264

8046

39316782

39317

633412

1511462

57192182

-627626

-68715051

-10599707

7831

36381815

36382

178750

169490

44015397

-857307

-46364364

-3000393

215

215000

-41749

791000

791

-153750

-147296

1210259

1063754

45113 45113

232519

-105001

-3157179

237215

8046

37172815

37173

25000

22194

45676539

-962308

-49758758

-4985151

-5656099

-3157179

155851

232519

1063754

151897 45113

2335167

-298983

204142

28213

401818

179533

-92694

150386

86221

-10717

399937

-53972

-2681396

-2393109

100000

146250

499900

1570900

-139780

96913

204842

581088

1573987

100334

-65851

-1999974

-884973

2201562

949848

201588

64875

1. NATURE OF OPERATIONS Biotricity Inc. (formerly MetaSolutions, Inc.) (the “Company”) was incorporated under the laws of the State of Nevada on August 29, 2012. iMedical Innovations Inc. (“iMedical”) was incorporated on July 3, 2014 under the laws of the Province of Ontario, Canada and became a wholly-owned subsidiary of Biotricity through reverse take-over. Both the Company and iMedical are engaged in research and development activities within the remote monitoring segment of preventative care. They are focused on a realizable healthcare business model that has an existing market and commercialization pathway. As such, its efforts to date have been devoted in building technology that enables access to this market through the development of a tangible product.

2. BASIS OF PRESENTATION, MEASUREMENT AND CONSOLIDATION The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“US GAAP”) for interim financial information and the Securities and Exchange Commission (“SEC”) instructions to Form 10-Q and Article 8 of SEC Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements and should be read in conjunction with Biotricity’s audited consolidated financial statements for the years ended March 31, 2021 and 2020 and their accompanying notes. The accompanying unaudited condensed consolidated financial statements are expressed in United States dollars (“USD”). In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation of financial position and results of operations for the interim periods presented have been reflected herein. Operating results for the interim periods presented herein are not necessarily indicative of the results that may be expected for the year ending March 31, 2022. The Company’s fiscal year-end is March 31. The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. Significant intercompany accounts and transactions have been eliminated. Certain prior year amounts have been reclassified to conform to the current year’s presentation. Liquidity and Basis of Presentation The Company is in the early stages of commercializing its first product. It is concurrently in development mode, operating a research and development program in order to develop an ecosystem of medical technologies, and, where required or deemed advisable, obtain regulatory approvals for, and commercialize other proposed products. The Company has incurred recurring losses from operations, and as at June 30, 2021, has an accumulated deficit of $68,715,051 and a working capital deficiency of $9,545,069. The Company launched its first commercial sales program as part of a limited market release, during the year ended March 31, 2019, using an experienced professional in-house sales team. A full market release ensued during the year ended March 31, 2020. Management anticipates the Company will continue on its revenue growth trajectory and improve its liquidity through continued business development and after additional equity or debt capitalization of the Company. The Company has developed and continues to pursue sources of funding that management believes if successful would be sufficient to support the Company’s operating plan and alleviate any substantial doubt as to its ability to meet its obligations at least for a period of one year from the date of these consolidated financial statements. During the fiscal year ended March 31, 2021, the Company closed a number of private placements offering of convertible notes, which have raised net cash proceeds of $11,375,690. During the fiscal quarter ended June 30, 2021, $1,157,500 of convertible notes issued during last year was converted into common shares. During the fiscal quarter ended June 30, 2021, the Company raised an additional $499,900 through government EIDL loan, and $250,000 through short term loans. The Company’s operating plan is predicated on a variety of assumptions including, but not limited to, the level of product demand, cost estimates, its ability to continue to raise additional financing and the state of the general economic environment in which the Company operates. There can be no assurance that these assumptions will prove to be accurate in all material respects, or that the Company will be able to successfully execute its operating plan. In the absence of additional appropriate financing, the Company may have to modify its operating plan or slow down the pace of development and commercialization of its proposed products. No assurance can be given that any future financing will be available or, if available, that it will be on terms that are satisfactory to the Company. Even if the Company is able to obtain additional financing, it may contain restrictions on our operations, in the case of debt financing or cause substantial dilution for our stockholders, in case of equity financing. Due to the disruption of the COVID-19 crisis, the Company’s business activities might be subject to certain level of adverse impact. To the date of the issuance of these financial statements, the Company is still assessing the impact on its business, results of operations, financial position and cash flows, which will be accounted for when the reliable estimates will become available.

-68715051

9545069

11375690

1157500

499900

250000

3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Use of Estimates The preparation of the consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Areas involving significant estimates and assumptions include: deferred income tax assets and related valuation allowance, accruals and valuation of derivatives, convertible promissory notes, stock options, and assumptions used in the going concern assessment. Actual results could differ from those estimates. These estimates are reviewed periodically, and, as adjustments become necessary, they are reported in earnings in the period in which they become known. Earnings (Loss) Per Share The Company has adopted the Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) Topic 260-10 which provides for calculation of “basic” and “diluted” earnings per share. Basic earnings per share includes no dilution and is computed by dividing net income or loss available to common stockholders by the weighted average number of common shares outstanding for the period. Diluted earnings per share reflect the potential dilution of securities that could share in the earnings of an entity. Diluted earnings per share exclude all potentially dilutive shares if their effect is anti-dilutive. There were no potentially dilutive shares outstanding as at June 30, 2021 and 2020. Fair Value of Financial Instruments ASC 820 defines fair value, establishes a framework for measuring fair value and expands required disclosure about fair value measurements of assets and liabilities. ASC 820-10 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820-10 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value: ● Level 1 – Valuation based on quoted market prices in active markets for identical assets or liabilities. ● Level 2 – Valuation based on quoted market prices for similar assets and liabilities in active markets. ● Level 3 – Valuation based on unobservable inputs that are supported by little or no market activity, therefore requiring management’s best estimate of what market participants would use as fair value. In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability. Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments or interest rates that are comparable to market rates. These financial instruments include cash, accounts receivable, deposits and other receivables, convertible promissory notes, and accounts payable and accrued liabilities. The Company’s cash and derivative liabilities, which are carried at fair values, are classified as a Level 1 and Level 3, respectively. The Company’s bank accounts are maintained with financial institutions of reputable credit, therefore, bear minimal credit risk. Leases The Company is the lessee in a lease contract when the Company obtains the right to use the asset. Operating leases are included in the line items right-of-use asset, lease obligation, current, and lease obligation, long-term in the consolidated balance sheet. Right-of-use (“ROU”) asset represents the Company’s right to use an underlying asset for the lease term and lease obligations represent the Company’s obligations to make lease payments arising from the lease, both of which are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. Leases with a lease term of 12 months or less at inception are not recorded on the consolidated balance sheet and are expensed on a straight-line basis over the lease term in our consolidated statement of income. The Company determines the lease term by agreement with lessor. As our lease do not provide an implicit interest rate, the Company uses the Company’s incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. Government loan Loans that were received from the federal government, which contain certain operating conditions and with terms of over twelve months, are recorded by the Company as long-term liabilities. Convertible Promissory Notes Payable and Derivative Instruments The Company has adopted the provisions of ASU 2017-11 to account for the down round features of warrants issued with private placements effective as of April 1, 2017. In doing so, warrants with a down round feature previously treated as derivative liabilities in the consolidated balance sheet and measured at fair value are henceforth treated as equity, with no adjustment for changes in fair value at each reporting period. Previously, the Company accounted for conversion options embedded in convertible notes in accordance with ASC 815. ASC 815 generally requires companies to bifurcate conversion options embedded in convertible notes from their host instruments and to account for them as free-standing derivative financial instruments. ASC 815 provides for an exception to this rule when convertible notes, as host instruments, are deemed to be conventional, as defined by ASC 815-40. The Company accounts for convertible notes deemed conventional and conversion options embedded in non-conventional convertible notes which qualify as equity under ASC 815, in accordance with the provisions of ASC 470-20, which provides guidance on accounting for convertible securities with beneficial conversion features. Accordingly, the Company records, as a discount to convertible notes, the intrinsic value of such conversion options based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt. Recently Issued Accounting Pronouncements In June 2016, the FASB issued ASU 2016-13, “Financial Instruments - Credit Losses (Topic 326) - Measurement of Credit Losses on Financial Instruments.” This pronouncement, along with subsequent ASUs issued to clarify provisions of ASU 2016-13, changes the impairment model for most financial assets and will require the use of an “expected loss” model for instruments measured at amortized cost. Under this model, entities will be required to estimate the lifetime expected credit loss on such instruments and record an allowance to offset the amortized cost basis of the financial asset, resulting in a net presentation of the amount expected to be collected on the financial asset. In developing the estimate for lifetime expected credit loss, entities must incorporate historical experience, current conditions, and reasonable and supportable forecasts. This pronouncement is effective for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2019. On November 19, 2019, the FASB issued ASU No. 2019-10, Financial Instruments—Credit Losses (Topic 326), finalized various effective date delays for private companies, not-for-profit organizations, and certain smaller reporting companies applying the credit losses (CECL), the revised effective date is January 2023. In July 2019, the FASB issued ASU 2019-07, Codification Updates to SEC Sections. This ASU amends various SEC paragraphs pursuant to the issuance of SEC Final Rule Releases No. 33-10532, Disclosure Update and Simplification, and Nos. 33-10231 and 33-10442, Investment Company Reporting Modernization. One of the changes in the ASU requires a presentation of changes in stockholders’ equity in the form of a reconciliation, either as a separate financial statement or in the notes to the financial statements, for the current and comparative year-to-date interim periods. The Company presented changes in stockholders’ equity as separate financial statements for the current and comparative year-to-date interim periods beginning on April 1, 2019. The additional elements of the ASU did not have a material impact on the Company’s consolidated financial statements. In December 2019, the FASB issued ASU No. 2019-12, Simplifying the Accounting for Income Taxes (“ASU 2019-12”), which simplifies the accounting for income taxes, eliminates certain exceptions within ASC 740, Income Taxes, and clarifies certain aspects of the current guidance to promote consistency among reporting entities. ASU 2019-12 is effective for fiscal years beginning after December 15, 2021. Most amendments within the standard are required to be applied on a prospective basis, while certain amendments must be applied on a retrospective or modified retrospective basis. The Company is currently evaluating the impacts of the provisions of ASU 2019-12 on its financial condition, results of operations, and cash flows. In March 2020, the FASB issued ASU No. 2030-20 Codification Improvements to Financial Instruments, An Amendment of the FASB Accounting Standards Codification: a) in ASU No. 2016-01, b) in Subtopic 820-10, c) for depository and lending institutions clarification in disclosure requirements, d) in Subtopic 470-50, e) in Subtopic 820-10, f) Interaction of Topic 842 and Topic 326, g) Interaction of the guidance in Topic 326 and Subtopic 860-20.The amendments in this Update represent changes to clarify or improve the Codification. The amendments make the Codification easier to understand and easier to apply by eliminating inconsistencies and providing clarifications. For public business entities updates under the following paragraphs: a), b), d) and e) are effective upon issuance of this final update. The effective date for c) is for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. The Company does not expect that the new guidance will significantly impact its consolidated financial statements. The Company continues to evaluate the impact of the new accounting pronouncement, including enhanced disclosure requirements, on our business processes, controls and systems.

Use of Estimates The preparation of the consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Areas involving significant estimates and assumptions include: deferred income tax assets and related valuation allowance, accruals and valuation of derivatives, convertible promissory notes, stock options, and assumptions used in the going concern assessment. Actual results could differ from those estimates. These estimates are reviewed periodically, and, as adjustments become necessary, they are reported in earnings in the period in which they become known.

Earnings (Loss) Per Share The Company has adopted the Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) Topic 260-10 which provides for calculation of “basic” and “diluted” earnings per share. Basic earnings per share includes no dilution and is computed by dividing net income or loss available to common stockholders by the weighted average number of common shares outstanding for the period. Diluted earnings per share reflect the potential dilution of securities that could share in the earnings of an entity. Diluted earnings per share exclude all potentially dilutive shares if their effect is anti-dilutive. There were no potentially dilutive shares outstanding as at June 30, 2021 and 2020.

Fair Value of Financial Instruments ASC 820 defines fair value, establishes a framework for measuring fair value and expands required disclosure about fair value measurements of assets and liabilities. ASC 820-10 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820-10 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value: ● Level 1 – Valuation based on quoted market prices in active markets for identical assets or liabilities. ● Level 2 – Valuation based on quoted market prices for similar assets and liabilities in active markets. ● Level 3 – Valuation based on unobservable inputs that are supported by little or no market activity, therefore requiring management’s best estimate of what market participants would use as fair value. In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability. Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments or interest rates that are comparable to market rates. These financial instruments include cash, accounts receivable, deposits and other receivables, convertible promissory notes, and accounts payable and accrued liabilities. The Company’s cash and derivative liabilities, which are carried at fair values, are classified as a Level 1 and Level 3, respectively. The Company’s bank accounts are maintained with financial institutions of reputable credit, therefore, bear minimal credit risk.

Leases The Company is the lessee in a lease contract when the Company obtains the right to use the asset. Operating leases are included in the line items right-of-use asset, lease obligation, current, and lease obligation, long-term in the consolidated balance sheet. Right-of-use (“ROU”) asset represents the Company’s right to use an underlying asset for the lease term and lease obligations represent the Company’s obligations to make lease payments arising from the lease, both of which are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. Leases with a lease term of 12 months or less at inception are not recorded on the consolidated balance sheet and are expensed on a straight-line basis over the lease term in our consolidated statement of income. The Company determines the lease term by agreement with lessor. As our lease do not provide an implicit interest rate, the Company uses the Company’s incremental borrowing rate based on the information available at commencement date in determining the present value of future payments.

Government loan Loans that were received from the federal government, which contain certain operating conditions and with terms of over twelve months, are recorded by the Company as long-term liabilities. Convertible Promissory Notes Payable and Derivative Instruments The Company has adopted the provisions of ASU 2017-11 to account for the down round features of warrants issued with private placements effective as of April 1, 2017. In doing so, warrants with a down round feature previously treated as derivative liabilities in the consolidated balance sheet and measured at fair value are henceforth treated as equity, with no adjustment for changes in fair value at each reporting period. Previously, the Company accounted for conversion options embedded in convertible notes in accordance with ASC 815. ASC 815 generally requires companies to bifurcate conversion options embedded in convertible notes from their host instruments and to account for them as free-standing derivative financial instruments. ASC 815 provides for an exception to this rule when convertible notes, as host instruments, are deemed to be conventional, as defined by ASC 815-40. The Company accounts for convertible notes deemed conventional and conversion options embedded in non-conventional convertible notes which qualify as equity under ASC 815, in accordance with the provisions of ASC 470-20, which provides guidance on accounting for convertible securities with beneficial conversion features. Accordingly, the Company records, as a discount to convertible notes, the intrinsic value of such conversion options based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt.

Recently Issued Accounting Pronouncements In June 2016, the FASB issued ASU 2016-13, “Financial Instruments - Credit Losses (Topic 326) - Measurement of Credit Losses on Financial Instruments.” This pronouncement, along with subsequent ASUs issued to clarify provisions of ASU 2016-13, changes the impairment model for most financial assets and will require the use of an “expected loss” model for instruments measured at amortized cost. Under this model, entities will be required to estimate the lifetime expected credit loss on such instruments and record an allowance to offset the amortized cost basis of the financial asset, resulting in a net presentation of the amount expected to be collected on the financial asset. In developing the estimate for lifetime expected credit loss, entities must incorporate historical experience, current conditions, and reasonable and supportable forecasts. This pronouncement is effective for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2019. On November 19, 2019, the FASB issued ASU No. 2019-10, Financial Instruments—Credit Losses (Topic 326), finalized various effective date delays for private companies, not-for-profit organizations, and certain smaller reporting companies applying the credit losses (CECL), the revised effective date is January 2023. In July 2019, the FASB issued ASU 2019-07, Codification Updates to SEC Sections. This ASU amends various SEC paragraphs pursuant to the issuance of SEC Final Rule Releases No. 33-10532, Disclosure Update and Simplification, and Nos. 33-10231 and 33-10442, Investment Company Reporting Modernization. One of the changes in the ASU requires a presentation of changes in stockholders’ equity in the form of a reconciliation, either as a separate financial statement or in the notes to the financial statements, for the current and comparative year-to-date interim periods. The Company presented changes in stockholders’ equity as separate financial statements for the current and comparative year-to-date interim periods beginning on April 1, 2019. The additional elements of the ASU did not have a material impact on the Company’s consolidated financial statements. In December 2019, the FASB issued ASU No. 2019-12, Simplifying the Accounting for Income Taxes (“ASU 2019-12”), which simplifies the accounting for income taxes, eliminates certain exceptions within ASC 740, Income Taxes, and clarifies certain aspects of the current guidance to promote consistency among reporting entities. ASU 2019-12 is effective for fiscal years beginning after December 15, 2021. Most amendments within the standard are required to be applied on a prospective basis, while certain amendments must be applied on a retrospective or modified retrospective basis. The Company is currently evaluating the impacts of the provisions of ASU 2019-12 on its financial condition, results of operations, and cash flows. In March 2020, the FASB issued ASU No. 2030-20 Codification Improvements to Financial Instruments, An Amendment of the FASB Accounting Standards Codification: a) in ASU No. 2016-01, b) in Subtopic 820-10, c) for depository and lending institutions clarification in disclosure requirements, d) in Subtopic 470-50, e) in Subtopic 820-10, f) Interaction of Topic 842 and Topic 326, g) Interaction of the guidance in Topic 326 and Subtopic 860-20.The amendments in this Update represent changes to clarify or improve the Codification. The amendments make the Codification easier to understand and easier to apply by eliminating inconsistencies and providing clarifications. For public business entities updates under the following paragraphs: a), b), d) and e) are effective upon issuance of this final update. The effective date for c) is for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. The Company does not expect that the new guidance will significantly impact its consolidated financial statements. The Company continues to evaluate the impact of the new accounting pronouncement, including enhanced disclosure requirements, on our business processes, controls and systems.

4. ACCOUNTS PAYABLE AND ACCRUED LIABILITIES SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20210630_zAmZWCKGtrn" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As at June 30, 2021 $</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_499_20210331_zMmnRAsFaGJ8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As at March 31, 2021 $</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_406_eus-gaap--AccountsPayableCurrent_iI_maOAPAAzZra_zC48bLU8ZeDe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Accounts payable</td><td style="width: 2%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 16%; font-weight: bold; text-align: right">1,282,921</td><td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">1,041,385</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--AccruedLiabilitiesCurrent_iI_maOAPAAzZra_zReaxvqBnb1i" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Accrued liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,678,032</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,478,739</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--OtherAccountsPayableAndAccruedLiabilities_iTI_mtOAPAAzZra_z0d3u7tCirig" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Accounts payable and accrued liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">2,960,953</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">2,520,124</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Accounts payable as at June 30, 2021, and March 31, 2021 include $177,840 and $182,995, respectively, due to a shareholder and executive of the Company, primarily as a result of that individual’s role as an employee. These amounts are unsecured, non-interest bearing and payable on demand.

SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20210630_zAmZWCKGtrn" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As at June 30, 2021 $</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_499_20210331_zMmnRAsFaGJ8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As at March 31, 2021 $</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_406_eus-gaap--AccountsPayableCurrent_iI_maOAPAAzZra_zC48bLU8ZeDe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Accounts payable</td><td style="width: 2%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 16%; font-weight: bold; text-align: right">1,282,921</td><td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">1,041,385</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--AccruedLiabilitiesCurrent_iI_maOAPAAzZra_zReaxvqBnb1i" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Accrued liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,678,032</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,478,739</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--OtherAccountsPayableAndAccruedLiabilities_iTI_mtOAPAAzZra_z0d3u7tCirig" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Accounts payable and accrued liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">2,960,953</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">2,520,124</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

1282921

1041385

1678032

1478739

2960953

2520124

177840

182995

5. CONVERTIBLE PROMISSORY NOTES AND SHORT TERM LOANS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">a)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The Company has issued various promissory notes and obtained several short term loans. The promissory notes and short-term loans are generally for a 1-year term at interest rates of between 10% and 12%, with allowance for the Company to repay early, and the possibility to convert into equity on the basis of mutual consent. Warrants to purchase the Company’s shares of common stock were granted pursuant to the issuance of certain promissory notes. Management has evaluated the terms of these notes issued in accordance with the guidance provided by ASC 470 and ASC 815 and concluded that there is no derivative or beneficial conversion feature attached to these notes.</td></tr></table> During the year ended March 31, 2021, the Company raised additional $500,000 in promissory notes that were subject to the same terms of the notes previously issued. During the year ended March 31, 2021, the Company made repayment of the notes and short term loan in the amount of $908,082, and one noteholder further paid the Company $67,941 to exercise warrants related to <span id="xdx_905_ecustom--StockIssuedDuringPeriodWarrantsSubscribeShares_pid_uShares_c20200401__20210331__srt--TitleOfIndividualAxis__custom--NoteHolderOneMember_zUWv6Kwc9mz2" title="Stock issued during period warrants subscribe shares">97,500 shares of the Company’s common stock. During the year ended March 31, 2021, one noteholder converted a $<span id="xdx_907_eus-gaap--DebtConversionConvertedInstrumentAmount1_pp0p0_c20200401__20210331__srt--TitleOfIndividualAxis__custom--NoteHolderOneMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zSN77MIzdMok" title="Debt instrument, convertible amount">100,000 note and $<span id="xdx_909_eus-gaap--InterestPayableCurrentAndNoncurrent_c20210331__srt--TitleOfIndividualAxis__custom--NoteHolderOneMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_pp0p0" title="Accrued interest">15,000 accrued interest into <span id="xdx_901_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_uShares_c20200401__20210331__srt--TitleOfIndividualAxis__custom--NoteHolderOneMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zeID9e4LMmN4" title="Debt instrument, convertible shares">115 Series A preferred shares. During the three months ended June 30, 2021, the Company raised additional $250,000 in short-term loans, that was subject to the same terms of short-term loans previously issued. During the three months ended June 30, 2021, the Company made repayments of notes and short term loan in the amount of $110,220. As at June 30, 2021, the Company had a balance in promissory note of $550,000 (March 31, 2021 - $600,577). As at June 30, 2021, the Company had a balance in short term loan of $1,250,000 (March 31, 2021 – $1,059,643) General and administrative expenses included interest expense on the above notes of $56,220 and $<span id="xdx_90E_eus-gaap--GeneralAndAdministrativeExpense_pp0p0_c20200401__20200630__us-gaap--IncomeStatementLocationAxis__custom--GeneralAndAdministrativeExpensesMember_zhlyphQ7Yppb" style="font: 10pt Times New Roman, Times, Serif">37,456 for the three months ended June 30, 2021 and 2020, respectively. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">(b)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">During the year ended March 31, 2021, the Company issued $11,275,500 (face value) in two series of convertible promissory notes (the “Series A Notes”) sold under subscription agreements to accredited investors. The Notes mature one year from the final closing date of the offering and accrue interest at 12% per annum.</td></tr> </table> For first series of Series A Notes, commencing six months following the Issuance Date, and at any time thereafter (provided the Holder has not received notice of the Company’s intent to prepay the note), at the sole election of the Holder, any amount of the outstanding principal and accrued interest of this note (the “Outstanding Balance”) may be converted into that number of shares of Common Stock equal to: (i) the Outstanding Balance divided by (ii) 75% of the volume weighted average price of the Common Stock for the 5 trading days prior to the Conversion Date (the conversion price). For the first series of Series A Notes, the notes will automatically convert into common stock (in each case, subject to the trading volume of the Company’s common stock being a minimum of $500,000 for each trading day in the 20 consecutive trading days immediately preceding the conversion date), upon the earlier to occur of (i) the Company’s common stock being listed on a national securities exchange, in which event the conversion price will be equal to 75% of the volume weighted average price of the common stock for the 20 trading days prior to the conversion date, or (ii) upon the closing of the Company’s next equity round of financing for gross proceeds of greater than $5,000,000, in which event the conversion price will be equal to 75% of the price per share of the common stock (or of the conversion price in the event of the sale of securities convertible into common stock) sold in such financing. The Company may, at its discretion redeem the notes for 115% of their face value plus accrued interest. For second series of Series A Notes, the notes could be converted into shares of common stock, at the option of the holder, commencing six months from issuance, at a conversion price equal to the lower of $4.00 per share or 75% of the volume weighted average price of the common stock for the five trading days prior to the conversion date For the second series of Series A Notes, the notes will automatically convert into common stock (in each case, subject to the trading volume of the Company’s common stock being a minimum of $500,000 for each trading day in the 20 consecutive trading days immediately preceding the conversion date), upon the earlier to occur of (i) the Company’s common stock being listed on a national securities exchange, in which event the conversion price will be equal to the lower of $4.00 per share or 75% of the volume weighted average price of the common stock for the 20 trading days prior to the conversion date, or (ii) upon the closing of the Company’s next equity round of financing for gross proceeds of greater than $5,000,000, in which event the conversion price will be equal to the lower of $4.00 per share or 75% of the price per share of the common stock (or of the conversion price in the event of the sale of securities convertible into common stock) sold in such financing. The Company may, at its discretion redeem the notes for 115% of their face value plus accrued interest. The Company was obligated to issue warrants that accompany the convertible notes and provide 50% warrant coverage. The warrants have a <span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20210331__us-gaap--DebtInstrumentAxis__custom--SeriesBNotesMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z8EOEJ216vY4" style="font: 10pt Times New Roman, Times, Serif">3-year term from date of issuance and an exercise price that is 120% of the 20-day volume weighted average price of the Company’s common shares at the time final closing. The Company was obligated to pay the placement agent of the first series of Series A Notes a 12% cash fee for $8,925,550 (face value) of the notes and 2.5% cash fee and other sundry expenses for the remaining $2,350,000 (face value) of the notes. Net proceeds to the Company from Series A Notes issuance up to March 31, 2021 amounted to $10,135,690 after payment of the relevant financing related fees. <span id="xdx_90F_ecustom--PlacementAgentFeesDescription_c20200401__20210331__us-gaap--DebtInstrumentAxis__custom--SeriesANotesMember__srt--TitleOfIndividualAxis__custom--PlacementAgentMember" style="font: 10pt Times New Roman, Times, Serif">The Company was also obligated to issue warrants to the placement agent that have a 10-year term and cover 12% of funds raised for $8,925,550 (face value) of the notes (first series) and 2.5% of funds raised for the remaining $2,350,000 (face value) of notes (second series), with an exercise price that is 120% of the 20-day volume weighted average price of the Company’s common shares at the time final closing. On final closing, which occurred on January 8, 2021, the warrants’ exercise price was struck at $1.06 per share. Prior to January 8, 2021 (final closing date), the Company determined that the conversion and redemption features, investor warrants and placement agent warrants contained in those Notes represented a single compound derivative liability that meets the requirements for liability classification under ASC 815. The Company accounted for these obligations by determining the fair value of the related derivative liabilities associated with the embedded conversion and redemption features, as well as investor warrants and placement agent warrants. The initial fair value of the derivative liabilities generated as a result of issuing the Series A Notes was $6,932,194 (Note 7). Subsequently, the exercise price of all warrants was concluded and locked to $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20210331__us-gaap--DebtInstrumentAxis__custom--SeriesBNotesMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zfSDQBKleZYa" title="Warrants exercise price">1.06 as of January 8, 2021. Since the exercise price was no longer a variable, the Company concluded that the noteholder and placement agent warrants should no longer be accounted for as a derivative liability in accordance with ASC 815 guidelines related to equity indexation and classification. The derivative liabilities related to those warrants were therefore marked to market as of January 8, 2021 and then transferred to equity (collectively, “End of warrants derivative treatment”) (Note 7 and Note 8). For the Series A Notes, The Company recognized debt issuance costs in the amount of $2,301,854 and treated these as a deduction from the convertible note liabilities directly, as a contra-liability, and amortized the debt issuance cost over the term of the Notes. The Company also recognized initial debt discount in the amount of $8,088,003 and accreted the interest over the remaining lives of those Notes. At March 31, 2021, the Company recorded $432,824 interest accruals for those notes’ balance. In connection with the foregoing, the Company relied upon the exemption from registration provided by Section 4(a)(2) under the Securities Act of 1933, as amended, for transactions not involving a public offering. During the year ended March 31, 2021, $739,000 (face value) of Series A Notes with unpaid interest were converted into <span id="xdx_90C_ecustom--SharesConvertedDuringThePeriodForUnpaidInterest_c20210401__20210630__us-gaap--DebtInstrumentAxis__custom--SeriesANotesMember_zpg8ERrQWTRd" title="Number of shares issued for unpaid interest">751,487 common shares. At March 31, 2021, 733,085 common shares were issued and an additional 18,402 common shares were to be issued subsequent to year end. During the quarter ended June 30, 2021, the 18,402 common shares were issued. At June 30, 2021, the Company recorded $656,902 interest accruals for the Series A Notes. In connection with the foregoing, the Company relied upon the exemption from registration provided by Section 4(a)(2) under the Securities Act of 1933, as amended, for transactions not involving a public offering. During the three months ended June 30, 2021, $1,157,500 (face value) of Series A Notes with unpaid interests were converted into 528,878 common shares, out of which 345,676 were common shares that would be issued subsequent to June 30, 2021. In addition, during the year ended March 31, 2021, the Company also issued $1,312,500 (face value) of convertible promissory notes (“Series B Notes”) to various accredited investors. Commencing six months following the issuance date, and at any time thereafter, subject to the Company’s Conversion Buyout clause, at the sole election of the holder, any amount of the outstanding principal and accrued interest of the note (the “outstanding balance”) may be converted into that number of shares of Common Stock equal to: (i) the outstanding balance divided by (ii) the Conversion Price. Partial conversions of the note shall have the effect of lowering the outstanding principal amount of the note. The holder may exercise such conversion right by providing written notice to the Company of such exercise in a form reasonably acceptable to the Company (a “conversion notice”). Conversion price means (subject in all cases to proportionate adjustment for stock splits, stock dividends, and similar transactions), seventy-five percent (75%) multiplied by the average of the three (3) lowest closing prices during the previous ten (10) trading days prior to the receipt of the conversion notice. The Series B Notes will automatically convert into common stock upon a merger, consolidation, exchange of shares, recapitalization, reorganization, as a result of which the Company’s common stock shall be changed into another class or classes of stock of the Company or another entity, or in the case of the sale of all or substantially all of the assets of the Company other than a complete liquidation of the Company. Within the first 180 days after the issuance date, the Company may, at its discretion redeem the notes for 115% of their face value plus accrued interest. The Company is obligated to issue warrants that accompany the convertible notes and provide 50% warrant coverage. The warrants have a <span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20210331__us-gaap--DebtInstrumentAxis__custom--SeriesBNotesMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zztp2WnDQTU8">3-year term from date of issuance and an exercise price that is $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20210331__us-gaap--DebtInstrumentAxis__custom--SeriesBNotesMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd">1.06 per share for <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20210331__us-gaap--DebtInstrumentAxis__custom--SeriesBNotesMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z7th4SSQ1WF3">100,000 warrant shares and $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20210331__us-gaap--DebtInstrumentAxis__custom--SeriesBNotesMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantOneMember_pdd">1.5 per share for 212,500 warrant shares. Net proceeds to the Company from convertible note issuances to March 31, 2021 amounted to $1,240,000 after the original issuance discount as well as payment of the financing related fees. The Company determined that the conversion and redemption features contained in the Series B Notes represented a single compound derivative liability that meets the requirements for liability classification under ASC 815. The Company accounted for these obligations by determining the fair value of the related derivative liability associated with the embedded conversion and redemption features. The initial fair value of the derivative liabilities generated as a result of issuing the Series B Notes was $497,042 (Note 7). The Company recognized debt issuance costs in the amount of $10,000 and treated these as a deduction from the convertible note liabilities directly, as a contra-liability, and amortized the debt issuance cost over the term of the Series B Notes. The Company recognized initial debt discount in the amount of $1,312,500 and accreted the interest over the remaining lives of those notes. At March 31, 2021, the Company recorded $8,360 interest accruals for the Series B Notes. In connection with the foregoing, the Company relied upon the exemption from registration provided by Section 4(a)(2) under the Securities Act of 1933, as amended, for transactions not involving a public offering. At June 30, 2021, the Company recorded $24,722 interest accruals for the Series B Notes. In connection with the foregoing, the Company relied upon the exemption from registration provided by Section 4(a)(2) under the Securities Act of 1933, as amended, for transactions not involving a public offering. SCHEDULE OF CONVERTIBLE PROMISSORY NOTES AND SHORT TERM LOANS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.5in"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Total</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">$</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; font-style: italic">Year ended March 31, 2021</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 80%; text-align: left">Face value of convertible notes issued</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_985_eus-gaap--DebtInstrumentFaceAmount_c20210331_pp0p0" style="width: 16%; text-align: right" title="Face value of Series A and Series B Notes issued">12,588,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Debt discount</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_pp0p0_di_c20210331_zkdv28iiomC5" style="text-align: right" title="Debt discount">(9,400,503</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Debt issuance cost</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--DeferredFinanceCostsNet_iNI_pp0p0_di_c20210331_zNjjrmqtE2C4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Debt issuance costs">(2,311,854</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Day 1 value of convertible notes issued</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_ecustom--ConvertibleNotesIssued_iI_pp0p0_c20210331_zF9Em9JxV8P4" style="text-align: right" title="Day 1 value of convertible notes issued">875,643</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Accretion of debt discount</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_ecustom--AccretionOfDebtDiscount_pp0p0_c20200401__20210331_zphQIzEPNeK1" style="text-align: right" title="Accretion of debt discount">1,802,807</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Amortization of debt issuance cost</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--AmortizationOfDebtDiscountPremium_pp0p0_c20200401__20210331_zuXFZYp0zOxf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Amortization of debt issuance cost">678,348</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total accretion and amortization expenses</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--DerivativeLossAccretionExpense_pp0p0_c20200401__20210331_zf0vtBpDKsce" style="text-align: right" title="Total accretion and amortization expenses">2,481,155</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Conversion to common shares (Note 8)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--ConversionOfStockAmountConverted1_iN_pp0p0_di_c20200401__20210331_zioUO2f9MeZ5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Conversion to common shares (Note 8)">(739,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; font-style: italic">Balance at March 31, 2021</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td id="xdx_980_ecustom--ConvertiblePromissoryNotesAndShortTermLoans_iI_pp0p0_c20210331_zZQDGw5nQjj3" style="font-weight: bold; text-align: right" title="Balance at March 31, 2021">2,617,798</td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; font-style: italic">Three months ended June 30, 2021</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accretion of debt discount</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_ecustom--AccretionOfDebtDiscount_c20210401__20210630_pp0p0" style="text-align: right">1,833,967</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Amortization of debt issuance cost</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--AmortizationOfDebtDiscountPremium_c20210401__20210630_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right">501,200</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total accretion and amortization expenses</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_ecustom--DerivativeLossAccretionExpense_pp0p0_c20210401__20210630_zyQTc5uUziT1" style="text-align: right" title="Total accretion and amortization expenses">2,335,167</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Conversion to common shares (Note 8)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--ConversionOfStockAmountConverted1_iN_pp0p0_di_c20210401__20210630_zgEmBX69EZZk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Conversion to common shares (Note 8)">(1,157,500</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; font-style: italic; padding-bottom: 2.5pt">Balance at June 30, 2021</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"> </td><td id="xdx_980_ecustom--ConvertiblePromissoryNotesAndShortTermLoans_iI_pp0p0_c20210630_zkDOc3ekXNIb" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Balance at June 30, 2021">3,795,465</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr> </table> General and administrative expenses include interest expense on the above debt instruments of $321,878 for the three months ended June 30, 2021 (June 30, 2020: $NIL).

P1Y

0.10

0.12

500000

908082

67941 97500

100000

15000

115

250000

110220

550000

600577

1250000

1059643

56220

37456

11275500

0.12

the notes will automatically convert into common stock (in each case, subject to the trading volume of the Company’s common stock being a minimum of $500,000 for each trading day in the 20 consecutive trading days immediately preceding the conversion date), upon the earlier to occur of (i) the Company’s common stock being listed on a national securities exchange, in which event the conversion price will be equal to 75% of the volume weighted average price of the common stock for the 20 trading days prior to the conversion date, or (ii) upon the closing of the Company’s next equity round of financing for gross proceeds of greater than $5,000,000, in which event the conversion price will be equal to 75% of the price per share of the common stock (or of the conversion price in the event of the sale of securities convertible into common stock) sold in such financing. The Company may, at its discretion redeem the notes for 115% of their face value plus accrued interest.

4.00

For the second series of Series A Notes, the notes will automatically convert into common stock (in each case, subject to the trading volume of the Company’s common stock being a minimum of $500,000 for each trading day in the 20 consecutive trading days immediately preceding the conversion date), upon the earlier to occur of (i) the Company’s common stock being listed on a national securities exchange, in which event the conversion price will be equal to the lower of $4.00 per share or 75% of the volume weighted average price of the common stock for the 20 trading days prior to the conversion date, or (ii) upon the closing of the Company’s next equity round of financing for gross proceeds of greater than $5,000,000, in which event the conversion price will be equal to the lower of $4.00 per share or 75% of the price per share of the common stock (or of the conversion price in the event of the sale of securities convertible into common stock) sold in such financing. The Company may, at its discretion redeem the notes for 115% of their face value plus accrued interest

The Company was obligated to issue warrants that accompany the convertible notes and provide 50% warrant coverage. The warrants have a

P3Y

The Company was obligated to pay the placement agent of the first series of Series A Notes a 12% cash fee for $8,925,550 (face value) of the notes and 2.5% cash fee and other sundry expenses for the remaining $2,350,000 (face value) of the notes 10135690 The Company was also obligated to issue warrants to the placement agent that have a 10-year term and cover 12% of funds raised for $8,925,550 (face value) of the notes (first series) and 2.5% of funds raised for the remaining $2,350,000 (face value) of notes (second series), with an exercise price that is 120% of the 20-day volume weighted average price of the Company’s common shares at the time final closing.

1.06

6932194

1.06

2301854

8088003

432824

739000

751487

733085

18402

656902

1157500

528878

345676

1312500

The holder may exercise such conversion right by providing written notice to the Company of such exercise in a form reasonably acceptable to the Company (a “conversion notice”). Conversion price means (subject in all cases to proportionate adjustment for stock splits, stock dividends, and similar transactions), seventy-five percent (75%) multiplied by the average of the three (3) lowest closing prices during the previous ten (10) trading days prior to the receipt of the conversion notice.

P3Y

1.06

100000

1.5

212500

1240000

497042

10000

1312500

8360

24722

SCHEDULE OF CONVERTIBLE PROMISSORY NOTES AND SHORT TERM LOANS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.5in"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Total</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">$</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; font-style: italic">Year ended March 31, 2021</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 80%; text-align: left">Face value of convertible notes issued</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_985_eus-gaap--DebtInstrumentFaceAmount_c20210331_pp0p0" style="width: 16%; text-align: right" title="Face value of Series A and Series B Notes issued">12,588,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Debt discount</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_pp0p0_di_c20210331_zkdv28iiomC5" style="text-align: right" title="Debt discount">(9,400,503</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Debt issuance cost</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--DeferredFinanceCostsNet_iNI_pp0p0_di_c20210331_zNjjrmqtE2C4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Debt issuance costs">(2,311,854</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Day 1 value of convertible notes issued</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_ecustom--ConvertibleNotesIssued_iI_pp0p0_c20210331_zF9Em9JxV8P4" style="text-align: right" title="Day 1 value of convertible notes issued">875,643</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Accretion of debt discount</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_ecustom--AccretionOfDebtDiscount_pp0p0_c20200401__20210331_zphQIzEPNeK1" style="text-align: right" title="Accretion of debt discount">1,802,807</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Amortization of debt issuance cost</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--AmortizationOfDebtDiscountPremium_pp0p0_c20200401__20210331_zuXFZYp0zOxf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Amortization of debt issuance cost">678,348</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total accretion and amortization expenses</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--DerivativeLossAccretionExpense_pp0p0_c20200401__20210331_zf0vtBpDKsce" style="text-align: right" title="Total accretion and amortization expenses">2,481,155</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Conversion to common shares (Note 8)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--ConversionOfStockAmountConverted1_iN_pp0p0_di_c20200401__20210331_zioUO2f9MeZ5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Conversion to common shares (Note 8)">(739,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; font-style: italic">Balance at March 31, 2021</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td id="xdx_980_ecustom--ConvertiblePromissoryNotesAndShortTermLoans_iI_pp0p0_c20210331_zZQDGw5nQjj3" style="font-weight: bold; text-align: right" title="Balance at March 31, 2021">2,617,798</td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; font-style: italic">Three months ended June 30, 2021</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accretion of debt discount</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_ecustom--AccretionOfDebtDiscount_c20210401__20210630_pp0p0" style="text-align: right">1,833,967</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Amortization of debt issuance cost</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--AmortizationOfDebtDiscountPremium_c20210401__20210630_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right">501,200</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total accretion and amortization expenses</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_ecustom--DerivativeLossAccretionExpense_pp0p0_c20210401__20210630_zyQTc5uUziT1" style="text-align: right" title="Total accretion and amortization expenses">2,335,167</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Conversion to common shares (Note 8)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--ConversionOfStockAmountConverted1_iN_pp0p0_di_c20210401__20210630_zgEmBX69EZZk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Conversion to common shares (Note 8)">(1,157,500</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; font-style: italic; padding-bottom: 2.5pt">Balance at June 30, 2021</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"> </td><td id="xdx_980_ecustom--ConvertiblePromissoryNotesAndShortTermLoans_iI_pp0p0_c20210630_zkDOc3ekXNIb" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Balance at June 30, 2021">3,795,465</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr> </table>

12588000

9400503

2311854

875643 1802807

678348

2481155

739000

2617798 1833967

501200

2335167

1157500

3795465

321878

6. FEDERALLY GUARANTEED LOANS Economic Injury Disaster Loan (“EIDL”) In April 2020, the Company received $<span id="xdx_90A_eus-gaap--ProceedsFromLoans_pp0p0_uUSD_c20200401__20200430__us-gaap--DebtInstrumentAxis__custom--CaptionedProgramMember__dei--LegalEntityAxis__custom--USSmallBusinessAdministrationMember_zh2xIkwwJ8Wj" title="Loan received">370,900 from the U.S. Small Business Administration (SBA) under the captioned program. <span id="xdx_905_ecustom--DescriptionDebtInstrumentTerm_c20200401__20200430__us-gaap--DebtInstrumentAxis__custom--CaptionedProgramMember__dei--LegalEntityAxis__custom--USSmallBusinessAdministrationMember_zAJAna3QCNqf" title="Description debt instrument term">The loan has a term of <span id="xdx_901_eus-gaap--DebtInstrumentTerm_dtY_c20200401__20200430__us-gaap--DebtInstrumentAxis__custom--CaptionedProgramMember__dei--LegalEntityAxis__custom--USSmallBusinessAdministrationMember_zSxDKBZOF10j" title="Debt instrument term">30 years and an interest rate of <span id="xdx_908_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20200430__us-gaap--DebtInstrumentAxis__custom--CaptionedProgramMember__dei--LegalEntityAxis__custom--USSmallBusinessAdministrationMember_zJHVc7pFeOvj" title="Interest rate">3.75%, without the requirement for payment in its first 12 months. The Company may prepay the loan without penalty at will. In May 2021, the Company received an additional $499,900 from the SBA under the same terms. Payment Protection Program (“PPP”) Loan In May 2020, Biotricity received loan proceeds of $1,200,000 (the “PPP Loan”) under the Paycheck Protection Program established by the Coronavirus Aid, Relief and Economic Security Act (the “CARES Act”) administered by the U.S. Small Business Administration (“SBA”). The Company met the criteria for the loan forgiveness and applied for the loan forgiveness in March 2021. For the year ended March 31, 2021, the Company recognized the loan forgiveness as a reduction to payroll expense in the amount of $1,156,453 and a reduction to the rent expense of $43,547. The loan forgiveness was granted by the SBA in May 2021. As at June 30, 2021, the balance of outstanding PPP loan is NIL (March 31, 2021: NIL).

370900

The loan has a term of

P30Y

0.0375

499900

1200000000000

1156453

43547

7. DERIVATIVE LIABILITIES On December 19, 2019 and January 9, 2020, the Company issued 7,830 Series A preferred shares; 6,000 of these were issued for cash proceeds of $<span id="xdx_905_ecustom--ProceedsFromIssuanceOfPreferredStock_pp0p0_c20191219__20200109__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zcRR6j0Hkyka" title="Proceeds from preferred stock">6,000,000 and 1,830 of these were issued on conversion of $1,830,000 of promissory notes that had previously been issued for cash proceeds in October 2019. On May 22, 2020, another 215 Series A preferred shares were issued as a result of a combined transaction that included the conversion of $100,000 in promissory notes (Note 5(a)) and $15,000 (Note 5(a)) in accrued interest for 115 preferred shares, as well as a purchase of 100 preferred shares for cash proceeds of $100,000. The Company analyzed the compound features of variable conversion and redemption embedded in this instrument, for potential derivative accounting treatment on the basis of ASC 820 (Fair Value in Financial Instruments), ASC 815 (Accounting for Derivative Instruments and Hedging Activities), Emerging Issues Task Force (“EITF”) Issue No. 00–19 and EITF 07–05, and determined that the embedded derivatives should be bundled and valued as a single, compound embedded derivative, bifurcated from the underlying equity instrument, treated as a derivative liability, and measured at fair value. SCHEDULE OF DERIVATIVE LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Total</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">$</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Derivative liabilities as at March 31, 2020</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right" title="Derivative liabilities, beginning balance">1,144,733</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Derivative fair value at issuance during fiscal 2021</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right" title="Derivative liabilities, beginning balance">41,749</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Change in fair value of derivatives</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right" title="Derivative liabilities, beginning balance">(776,440</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 80%; font-weight: bold">Derivative liabilities as at March 31, 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_pp0p0_c20210401__20210630_zvypTnUVi2Ol" style="width: 16%; text-align: right" title="Derivative liabilities, beginning balance">410,042</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Change in fair value of derivatives during the period</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_iN_pp0p0_di_c20210401__20210630_zIiNVu1FcoGj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Change in fair value of derivatives">(203,525</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; padding-bottom: 2.5pt">Derivative liabilities as at June 30, 2021</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_pp0p0_c20210401__20210630_zhz5lRzIN698" style="border-bottom: Black 2.5pt double; text-align: right" title="Derivative liabilities, beginning balance">206,517</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The lattice methodology was used to value the derivative components, using the following assumptions: SCHEDULE OF DERIVATIVE COMPONENTS VALUATION ASSUMPTIONS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Assumptions</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 72%; text-align: left">Dividend yield</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_dp_uPure_c20210630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zhI5Ptot3MNg" style="width: 24%; text-align: right" title="Derivative liability, measurement input">12</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Risk-free rate for term</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_dp_uPure_c20210630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zxbs4MivZve9" title="Derivative liability, measurement input">0.26% – <span id="xdx_909_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_dp_uPure_c20210630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_zSEK1FxOqTg7" title="Derivative liability, measurement input">1.7</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_dp_uPure_c20210630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember_zCeeF9g6NVjg" style="font-size: 10pt">111.7% - <span id="xdx_908_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_dp_uPure_c20210630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember_zZG0Z0FDbLkl">121.5</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Remaining terms (Years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_ecustom--DerivativeLiabilityRemainingTerm_dtY_c20210401__20210630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember_z6HHvVd01lpi" title="Derivative liability, remaining term (Years)">2.50 to <span id="xdx_90A_ecustom--DerivativeLiabilityRemainingTerm_dtY_c20210401__20210630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember_zAxzrX1DdCS9" title="Derivative liability, remaining term (Years)">5.03</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Stock price ($ per share)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">$0.650 and $3.145</td><td style="text-align: left"> </td></tr> </table> In addition, the Company recorded derivative liabilities related to the conversion and redemption features of the convertible notes, as well as warrants that were issued in connection with the convertible notes, during the year ended March 31, 2021 (Note 5(b)). As the warrant exercise price became final and locked, the derivative liabilities related to those warrants were marked to market and transferred to equity (Note 5(b)). Any noteholder and placement agent warrants that were issued after the finalization of exercise price was accounted for as equity. <p id="xdx_898_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_hus-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_z8HlEAByiu2g" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"> SCHEDULE OF DERIVATIVE LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Total</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">$</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; font-weight: bold">For the year ended March 31, 2021</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Derivative fair value at issuance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">Series A notes (Note 5(b))</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_pp0p0_c20200401__20210331__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember__us-gaap--DebtInstrumentAxis__custom--SeriesANoteMember_zqXmf8wUOnG2" style="width: 16%; text-align: right" title="Derivative fair value at issuance during fiscal 2021">6,932,194</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Series B notes (Note 5(b))</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_c20200401__20210331__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember__us-gaap--DebtInstrumentAxis__custom--SeriesBNoteMember_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="Derivative fair value at issuance during fiscal 2021">497,042</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td id="xdx_985_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_c20200401__20210331__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_pp0p0" style="font-weight: bold; text-align: right" title="Derivative fair value at issuance during fiscal 2021">7,429,236</td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Fair value change upon end of warrants derivative treatment (Note 5(b))</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_ecustom--FairValueChangeUponEndOfWarrantsDerivativeTreatment_c20200401__20210331__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_pp0p0" style="text-align: right" title="Fair value change upon end of warrants derivative treatment (Note 5(b))">(82,444</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Carrying amount of warrants transferred equity upon end of warrants derivative treatment (Note 5(b))</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--DebtConversionConvertedInstrumentAmount1_iN_pp0p0_di_c20200401__20210331__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zkf63ku3COC9" style="text-align: right" title="Carrying amount of warrants transferred equity upon end of warrants derivative treatment (Note 5(b))">(3,937,664</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Conversion to common shares (Note 5(b))</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ConversionOfStockAmountConverted1_c20200401__20210331__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_pp0p0" style="text-align: right" title="Conversion to common shares (Note 5(b))">(225,284</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Change in fair value of derivative liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_c20200401__20210331__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="Change in fair value of derivatives">450,012</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; font-weight: bold; font-style: italic">Balance at March 31, 2021</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td id="xdx_981_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_pp0p0_c20200401__20210331__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zWVFXbdrZfSk" style="font-weight: bold; text-align: right" title="Derivative liabilities, ending balance">3,633,856</td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; font-weight: bold; font-style: italic">For the three months ended June 30, 2021</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Conversion to common shares (Note 5(b))</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(403,108</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; font-weight: bold; font-style: italic"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Change in fair value of derivative liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_iN_pp0p0_di_c20210401__20210630__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zjSf4CJqwtr2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Derivative liabilities, beginning balance">502,508</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; font-weight: bold; font-style: italic; padding-bottom: 2.5pt">Balance at June 30, 2021</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"> </td><td id="xdx_982_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_pp0p0_c20210401__20210630__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zbV1jXH10Bh1" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Derivative liabilities, ending balance">3,733,256</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr> </table> <p id="xdx_897_eus-gaap--ScheduleOfAssumptionsUsedTableTextBlock_hus-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_z2KOVaSKH25k" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The monte carlo methodology was used to value the convertible note and warrant derivative components, using the following assumptions: SCHEDULE OF DERIVATIVE COMPONENTS VALUATION ASSUMPTIONS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Conversion and redemption features</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%; text-align: left">Risk-free rate for term (%)</td><td style="width: 2%"> </td> <td style="width: 20%; text-align: right"><span id="xdx_90F_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_dp_uPure_c20210630__us-gaap--DebtInstrumentAxis__custom--ConversionAndRedemptionFeaturesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zL5gHtyaZNn1" title="Derivative liability, measurement input">0.10 - <span id="xdx_90B_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_dp_uPure_c20210630__us-gaap--DebtInstrumentAxis__custom--ConversionAndRedemptionFeaturesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_zAVXl3IKsGdi" title="Derivative liability, measurement input">0.19</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Volatility (%)</td><td> </td> <td style="text-align: right"><span id="xdx_90B_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_dp_uPure_c20210630__us-gaap--DebtInstrumentAxis__custom--ConversionAndRedemptionFeaturesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember_zy58aAUfr8y6" title="Derivative liability, measurement input">89.2 – <span id="xdx_90A_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_dp_uPure_c20210630__us-gaap--DebtInstrumentAxis__custom--ConversionAndRedemptionFeaturesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember_zJLuwOgsz72b" title="Derivative liability, measurement input">116.5</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Remaining terms (Years)</td><td> </td> <td style="text-align: right"><span id="xdx_90D_ecustom--DerivativeLiabilityRemainingTerm_dtY_c20210401__20210630__us-gaap--DebtInstrumentAxis__custom--ConversionAndRedemptionFeaturesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember_zzde4A5oXk9l" title="Derivative liability, remaining term (Years)">0.53 –<span id="xdx_902_ecustom--DerivativeLiabilityRemainingTerm_dtY_c20210401__20210630__us-gaap--DebtInstrumentAxis__custom--ConversionAndRedemptionFeaturesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember_z02HkxV78IHg" title="Derivative liability, remaining term (Years)"> 0.68</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Stock price ($ per share)</td><td> </td> <td style="text-align: right"><span id="xdx_908_ecustom--DerivativeStockPrice_iI_pid_uUSDPShares_c20210630__us-gaap--DebtInstrumentAxis__custom--ConversionAndRedemptionFeaturesMember__srt--RangeAxis__srt--MinimumMember_zYungkhOiQ2e" title="Stock price">0.72 – <span id="xdx_90A_ecustom--DerivativeStockPrice_iI_pid_uUSDPShares_c20210630__us-gaap--DebtInstrumentAxis__custom--ConversionAndRedemptionFeaturesMember__srt--RangeAxis__srt--MaximumMember_zMU1MrTJp3Zd" title="Stock price">4.15</td></tr> </table>

7830

6000

6000000

1830

1830000

215

100000

15000

115

100

100000

SCHEDULE OF DERIVATIVE LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Total</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">$</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Derivative liabilities as at March 31, 2020</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right" title="Derivative liabilities, beginning balance">1,144,733</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Derivative fair value at issuance during fiscal 2021</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right" title="Derivative liabilities, beginning balance">41,749</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Change in fair value of derivatives</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right" title="Derivative liabilities, beginning balance">(776,440</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 80%; font-weight: bold">Derivative liabilities as at March 31, 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_pp0p0_c20210401__20210630_zvypTnUVi2Ol" style="width: 16%; text-align: right" title="Derivative liabilities, beginning balance">410,042</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Change in fair value of derivatives during the period</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_iN_pp0p0_di_c20210401__20210630_zIiNVu1FcoGj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Change in fair value of derivatives">(203,525</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; padding-bottom: 2.5pt">Derivative liabilities as at June 30, 2021</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_pp0p0_c20210401__20210630_zhz5lRzIN698" style="border-bottom: Black 2.5pt double; text-align: right" title="Derivative liabilities, beginning balance">206,517</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

1144733

-41749

-776440

410042

203525

206517

The lattice methodology was used to value the derivative components, using the following assumptions: SCHEDULE OF DERIVATIVE COMPONENTS VALUATION ASSUMPTIONS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Assumptions</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 72%; text-align: left">Dividend yield</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_dp_uPure_c20210630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zhI5Ptot3MNg" style="width: 24%; text-align: right" title="Derivative liability, measurement input">12</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Risk-free rate for term</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_dp_uPure_c20210630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zxbs4MivZve9" title="Derivative liability, measurement input">0.26% – <span id="xdx_909_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_dp_uPure_c20210630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_zSEK1FxOqTg7" title="Derivative liability, measurement input">1.7</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_dp_uPure_c20210630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember_zCeeF9g6NVjg" style="font-size: 10pt">111.7% - <span id="xdx_908_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_dp_uPure_c20210630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember_zZG0Z0FDbLkl">121.5</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Remaining terms (Years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_ecustom--DerivativeLiabilityRemainingTerm_dtY_c20210401__20210630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember_z6HHvVd01lpi" title="Derivative liability, remaining term (Years)">2.50 to <span id="xdx_90A_ecustom--DerivativeLiabilityRemainingTerm_dtY_c20210401__20210630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember_zAxzrX1DdCS9" title="Derivative liability, remaining term (Years)">5.03</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Stock price ($ per share)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">$0.650 and $3.145</td><td style="text-align: left"> </td></tr> </table>

0.12

0.0026

0.017

1.117

1.215

P2Y6M P5Y10D 0.650 3.145

<p id="xdx_898_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_hus-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_z8HlEAByiu2g" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"> SCHEDULE OF DERIVATIVE LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Total</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">$</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; font-weight: bold">For the year ended March 31, 2021</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Derivative fair value at issuance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">Series A notes (Note 5(b))</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_pp0p0_c20200401__20210331__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember__us-gaap--DebtInstrumentAxis__custom--SeriesANoteMember_zqXmf8wUOnG2" style="width: 16%; text-align: right" title="Derivative fair value at issuance during fiscal 2021">6,932,194</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Series B notes (Note 5(b))</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_c20200401__20210331__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember__us-gaap--DebtInstrumentAxis__custom--SeriesBNoteMember_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="Derivative fair value at issuance during fiscal 2021">497,042</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td id="xdx_985_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_c20200401__20210331__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_pp0p0" style="font-weight: bold; text-align: right" title="Derivative fair value at issuance during fiscal 2021">7,429,236</td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Fair value change upon end of warrants derivative treatment (Note 5(b))</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_ecustom--FairValueChangeUponEndOfWarrantsDerivativeTreatment_c20200401__20210331__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_pp0p0" style="text-align: right" title="Fair value change upon end of warrants derivative treatment (Note 5(b))">(82,444</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Carrying amount of warrants transferred equity upon end of warrants derivative treatment (Note 5(b))</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--DebtConversionConvertedInstrumentAmount1_iN_pp0p0_di_c20200401__20210331__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zkf63ku3COC9" style="text-align: right" title="Carrying amount of warrants transferred equity upon end of warrants derivative treatment (Note 5(b))">(3,937,664</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Conversion to common shares (Note 5(b))</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ConversionOfStockAmountConverted1_c20200401__20210331__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_pp0p0" style="text-align: right" title="Conversion to common shares (Note 5(b))">(225,284</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Change in fair value of derivative liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_c20200401__20210331__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="Change in fair value of derivatives">450,012</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; font-weight: bold; font-style: italic">Balance at March 31, 2021</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td id="xdx_981_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_pp0p0_c20200401__20210331__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zWVFXbdrZfSk" style="font-weight: bold; text-align: right" title="Derivative liabilities, ending balance">3,633,856</td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; font-weight: bold; font-style: italic">For the three months ended June 30, 2021</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Conversion to common shares (Note 5(b))</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(403,108</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; font-weight: bold; font-style: italic"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Change in fair value of derivative liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_iN_pp0p0_di_c20210401__20210630__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zjSf4CJqwtr2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Derivative liabilities, beginning balance">502,508</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; font-weight: bold; font-style: italic; padding-bottom: 2.5pt">Balance at June 30, 2021</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"> </td><td id="xdx_982_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_pp0p0_c20210401__20210630__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zbV1jXH10Bh1" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Derivative liabilities, ending balance">3,733,256</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr> </table>

6932194

497042

7429236

-82444

3937664

-225284

450012

3633856

-403108

-502508

3733256

<p id="xdx_897_eus-gaap--ScheduleOfAssumptionsUsedTableTextBlock_hus-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_z2KOVaSKH25k" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The monte carlo methodology was used to value the convertible note and warrant derivative components, using the following assumptions: SCHEDULE OF DERIVATIVE COMPONENTS VALUATION ASSUMPTIONS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Conversion and redemption features</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%; text-align: left">Risk-free rate for term (%)</td><td style="width: 2%"> </td> <td style="width: 20%; text-align: right"><span id="xdx_90F_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_dp_uPure_c20210630__us-gaap--DebtInstrumentAxis__custom--ConversionAndRedemptionFeaturesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zL5gHtyaZNn1" title="Derivative liability, measurement input">0.10 - <span id="xdx_90B_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_dp_uPure_c20210630__us-gaap--DebtInstrumentAxis__custom--ConversionAndRedemptionFeaturesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_zAVXl3IKsGdi" title="Derivative liability, measurement input">0.19</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Volatility (%)</td><td> </td> <td style="text-align: right"><span id="xdx_90B_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_dp_uPure_c20210630__us-gaap--DebtInstrumentAxis__custom--ConversionAndRedemptionFeaturesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember_zy58aAUfr8y6" title="Derivative liability, measurement input">89.2 – <span id="xdx_90A_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_dp_uPure_c20210630__us-gaap--DebtInstrumentAxis__custom--ConversionAndRedemptionFeaturesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember_zJLuwOgsz72b" title="Derivative liability, measurement input">116.5</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Remaining terms (Years)</td><td> </td> <td style="text-align: right"><span id="xdx_90D_ecustom--DerivativeLiabilityRemainingTerm_dtY_c20210401__20210630__us-gaap--DebtInstrumentAxis__custom--ConversionAndRedemptionFeaturesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember_zzde4A5oXk9l" title="Derivative liability, remaining term (Years)">0.53 –<span id="xdx_902_ecustom--DerivativeLiabilityRemainingTerm_dtY_c20210401__20210630__us-gaap--DebtInstrumentAxis__custom--ConversionAndRedemptionFeaturesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember_z02HkxV78IHg" title="Derivative liability, remaining term (Years)"> 0.68</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Stock price ($ per share)</td><td> </td> <td style="text-align: right"><span id="xdx_908_ecustom--DerivativeStockPrice_iI_pid_uUSDPShares_c20210630__us-gaap--DebtInstrumentAxis__custom--ConversionAndRedemptionFeaturesMember__srt--RangeAxis__srt--MinimumMember_zYungkhOiQ2e" title="Stock price">0.72 – <span id="xdx_90A_ecustom--DerivativeStockPrice_iI_pid_uUSDPShares_c20210630__us-gaap--DebtInstrumentAxis__custom--ConversionAndRedemptionFeaturesMember__srt--RangeAxis__srt--MaximumMember_zMU1MrTJp3Zd" title="Stock price">4.15</td></tr> </table>

0.0010

0.0019

0.892

1.165

P0Y6M10D P0Y8M4D 0.72 4.15

8. STOCKHOLDERS’ DEFICIENCY a) Authorized stock As at June 30, 2021, the Company is authorized to issue 125,000,000 (March 31, 2021 – 125,000,000) shares of common stock ($0.001 par value) and 10,000,000 (March 31, 2021 – 10,000,000) shares of preferred stock ($0.001 par value), 20,000 of which (March 31, 2021 – 20,000) are designated shares of Series A preferred stock ($0.001 par value) At June 30, 2021, common shares and shares directly exchangeable into equivalent common shares that were issued and outstanding totaled <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_uShares_c20210401__20210630__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember__srt--TitleOfIndividualAxis__custom--ShareholdersMember_zOHVD25pxXG5">39,316,782 (March 31, 2021 – <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20200401__20210331__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember__srt--TitleOfIndividualAxis__custom--ShareholdersMember_pdd">39,014,942); these were comprised of 37,850,064 (March 31, 2021 – 36,124,964) shares of common stock and 1,466,718 (March 31, 2021 – 2,889,978) exchangeable shares. There is currently one share of the Special Voting Preferred Stock issued and outstanding, held by one holder of record, which is the Trustee in accordance with the terms of the Trust Agreement. The Company has also issued a Series A preferred stock, $0.001 par value; 20,000 shares have been designated as authorized (as at June 30 and March 31, 2021); 8,045 Series A preferred shares were issued and outstanding as at June 30 and March 31, 2021. b) Exchange Agreement On February 2, 2016, the Company was formed through reverse-take-over: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The Company issued approximately <span id="xdx_902_ecustom--CommonStockExchangeDescription_c20210401__20210630__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember__srt--TitleOfIndividualAxis__custom--ShareholdersMember_z0qQSxW3LWJ4" title="Common stock exchange description">1.197 shares of its common stock in exchange for each common share of iMedical held by the iMedical shareholders who in general terms, are not residents of Canada (for the purposes of the Income Tax Act (Canada). Accordingly, the Company issued 13,376,947 shares;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Shareholders of iMedical who in general terms, are Canadian residents (for the purposes of the Income Tax Act (Canada)) received approximately <span id="xdx_903_ecustom--CommonStockExchangeDescription_c20210401__20210630__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember__srt--TitleOfIndividualAxis__custom--ExchangecoMember_zRjWhE7PYnBc" title="Common stock exchange description">1.197 Exchangeable Shares in the capital of Exchangeco in exchange for each common share of iMedical held. Accordingly, the Company issued 9,123,031 Exchangeable Shares;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Each outstanding option to purchase common shares in iMedical (whether vested or unvested) was exchanged, without any further action or consideration on the part of the holder of such option, for approximately <span id="xdx_905_ecustom--CommonStockExchangeDescription_c20210401__20210630__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember__srt--StatementScenarioAxis__custom--OptionsMember_zX1lcUIPxNvd" title="Common stock exchange description">1.197 economically equivalent replacement options with an inverse adjustment to the exercise price of the replacement option to reflect the exchange ratio of approximately 1.197:1;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Each outstanding warrant to purchase common shares in iMedical was adjusted, in accordance with the terms thereof, such that it entitles the holder to receive approximately <span id="xdx_90D_ecustom--CommonStockExchangeDescription_c20210401__20210630__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ziAHzfse15Nj" title="Common stock exchange description">1.197 shares of the common stock of the Company for each warrant, with an inverse adjustment to the exercise price of the warrants to reflect the exchange ratio of approximately 1.197:1</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Each outstanding advisor warrant to purchase common shares in iMedical was adjusted, in accordance with the terms thereof, such that it entitles the holder to receive approximately <span id="xdx_908_ecustom--CommonStockExchangeDescription_c20200401__20210331__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--AdvisorWarrantMember" title="Common stock exchange description">1.197 shares of the common stock of the Company for each advisor warrant, with an inverse adjustment to the exercise price of the Advisor Warrants to reflect the exchange ratio of approximately 1.197:1; and</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_904_eus-gaap--ConversionOfStockDescription_c20210401__20210630__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember__us-gaap--DebtInstrumentAxis__custom--ElevenPercentageSecuredConvertiblePromissoryNotesMember_zaAAoRK3wd9e" title="Conversion description">The outstanding 11% secured convertible promissory notes of iMedical were adjusted, in accordance with the adjustment provisions thereof, as and from closing, so as to permit the holders to convert (and in some circumstances permit the Company to force the conversion of) the convertible promissory notes into shares of the common stock of the Company at a <span id="xdx_901_ecustom--DiscountPercentageForPurchasePricePerShares_pid_dp_uPure_c20210401__20210630__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember__us-gaap--DebtInstrumentAxis__custom--ElevenPercentageSecuredConvertiblePromissoryNotesMember_z0QXZQe6HGW2" title="Discount percentage for purchase price per shares">25% discount to purchase price per share in Biotricity’s next offering.</td></tr> </table> Issuance of common stock, exchangeable shares and cancellation of shares in connection with the reverse takeover transaction as explained above represents recapitalization of capital retroactively adjusting the accounting acquirer’s legal capital to reflect the legal capital of the accounting acquiree. c) Share issuances Share issuances during the year ended March 31, 2021 During the year ended March 31, 2021, the Company recorded preferred stock dividends for the Series A preferred stock in amount of $962,148 (2020 - $257,927) and made a payment in the amount of $602,969 (2020 - $180,000). During the year ended March 31, 2021, the Company issued 733,085 common shares were issued in connection with conversion of convertible notes (Note 5(b)) with another <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_uShares_c20200401__20210331__srt--StatementScenarioAxis__custom--IssuanceOfCommonSharesMember__us-gaap--SubsidiarySaleOfStockAxis__custom--AdvisorMember_zbmVKVAcieBk" title="Number of shares issued">18,402 that would be issued subsequent to year end. The total amounts of debts settled is in amount of $<span id="xdx_906_eus-gaap--RepaymentsOfDebt_c20200401__20210331__srt--StatementScenarioAxis__custom--IssuanceOfCommonSharesMember__us-gaap--SubsidiarySaleOfStockAxis__custom--AdvisorMember_pp0p0" title="Debt settlement amount">1,011,286 that composed of face value of convertible promissory notes in amount of $739,000 (Note 5(b), carrying amount of conversion and redemption feature derived from notes in amount of $<span id="xdx_906_eus-gaap--DebtInstrumentConvertibleBeneficialConversionFeature_c20200401__20210331__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember_pp0p0" title="Conversion redemption feature amount">225,284 and unpaid interest in amount of $47,002. The fair value of the shares issued and to be issued was determined based on the market price upon conversion and was in the amount of $1,076,561 and $38,460 respectively. The difference between amounts of debts settled and fair value of common shares issued was in the amount of $<span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp0p0_c20200401__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember_z3UWHChsVtRc" title="Number of common shares issued, value">103,375 and was recorded as loss on conversion of convertible promissory notes in statement of operations. During the year ended March 31, 2021, the Company issued 1,900,042 common shares for services provided and for warrants exercised. During the year ended March 31, 2021, the Company also issued an aggregate of 898,084 shares of its common stock to investors as part of the one-for-one exchange of previously issued exchangeable shares into the Company’s Common Stock, which is a non-cash transaction. Share issuances during the three months ended June 30, 2021 During the three months ended June 30, 2021, the Company issued 183,202 common shares in connection with conversion of convertible notes (Note 5(b)) with another <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_uShares_c20210401__20210630__srt--StatementScenarioAxis__custom--IssuanceOfCommonSharesMember__us-gaap--SubsidiarySaleOfStockAxis__custom--AdvisorMember_zweUQrplckI1">345,676 that would be issued subsequent to June 30, 2021. The total amounts of debts settled is in amount of $<span id="xdx_905_eus-gaap--RepaymentsOfDebt_pp0p0_c20210401__20210630__srt--StatementScenarioAxis__custom--IssuanceOfCommonSharesMember__us-gaap--SubsidiarySaleOfStockAxis__custom--AdvisorMember_z2wNOQ2D9mmb">1,642,049 that composed of face value of convertible promissory notes in amount of $1,157,500 (Note 5(b)), carrying amount of conversion and redemption feature derived from notes in amount of $403,108 and unpaid interest in amount of $81,441. The fair value of the shares issued and to be issued was determined based on the market price upon conversion and was in the amount of $479,760 and $1,190,502 respectively. The difference, that represented a loss on conversion, between amounts of debts settled and fair value of common shares issued was in the amount of $<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp0p0_c20210401__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember_zlMCi3wk8Rza">28,213 and was recorded as other income on conversion of convertible promissory notes in statement of operations. During the three months ended June 30, 2021, the Company also issued an aggregate of 1,423,260 shares of its common stock to investors as part of the one-for-one exchange of previously issued exchangeable shares into the Company’s Common Stock, which is a non-cash transaction. d) Shares to be issued During the three months ended June 30, 2021, the Company issued 18,402 of previously to be issued shares, in connection with convertible note conversions. As of June 30, 2021, the Company has recognized its contractual obligations for 345,676 shares to be issued, in connection with conversions of convertible notes that took place in the quarter (Note 5(b)), with fair value of shares to be issued of $<span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pp0p0_c20210630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember_zThpczbn768k">1,190,502, determined based on the market price upon conversion. In addition, the Company recognized its contractual obligations for <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20210630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember_zVA5bQj4Rw8k" title="Number of shares issued for warrants">55,493 shares to be issued for warrant exercises request received but not yet processed as of quarter end. e) Warrant issuances and exercises Warrant exercises and issuances during the year ended March 31, 2021 During the year ended March 31, 2021, 97,500 warrants were exercised (2020 – nil) pursuant to receipt of exercise proceeds of $67,941. (Note 5(a)) During the year ended March 31, 2021, the Company issued <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensationGross_pid_uShares_c20200401__20210331__srt--TitleOfIndividualAxis__custom--AdvisorAndConsultantTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zqRMMBACPsb5" title="Number of common stock compensation for services">449,583 warrants as compensation for advisor and consultant services which were fair valued. The vested portion in current year and from previous year at $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensationGross_c20200401__20210331__srt--TitleOfIndividualAxis__custom--AdvisorAndConsultantTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pp0p0" title="Number of common stock compensation for services, value">275,801 and expensed in general and administrative expenses, with a corresponding credit to additional paid in capital. As of December 31, 2020, the Company extended the expiry dates of <span id="xdx_90F_ecustom--WarrantsIssued_c20200401__20210331__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" title="Warrants issued">788,806 warrants previously issued to an executive of the Company, in order to extend their term from <span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190401__20200331__srt--TitleOfIndividualAxis__custom--AdvisorAndConsultantTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zaGmgI4ufL65" title="Expected life">3 to <span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190401__20200331__srt--TitleOfIndividualAxis__custom--AdvisorAndConsultantTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_znS8DdgvnH06" title="Expected life">10 years in accord with the same term extension made to the options of all other Company employees in fiscal 2020. As part of this revision in terms, <span id="xdx_906_ecustom--WarrantsIssued_c20190401__20200331__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" title="Warrants issued">288,806 of these same warrants, previously issued and expensed, were repriced to reflect current market conditions; the resulting increase in the fair value of these warrants of $<span id="xdx_908_eus-gaap--FairValueAdjustmentOfWarrants_c20200401__20210331__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pp0p0" title="Fair value of warrants">464,971 was expensed to general and administrative expenses. In addition, the Company issued <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--BrokersMember_pdd" title="Number of warrants issued">1,065,857 warrants to brokers, and <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--ConvertibleNoteholdersMember_pdd" title="Number of warrants issued">5,631,132 warrants to convertible note holders, in connection with the convertible note issuance (Note 5(b)). The warrants’ fair value has been estimated using a monte carlo model (Note 7), which were initially recorded as derivative liabilities, then recorded as equity upon the end of derivative treatment of such warrants (Note 5(b) and Note 7). During the three months ended June 30, 2021, the Company issued <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensationGross_pid_uShares_c20210401__20210630__srt--TitleOfIndividualAxis__custom--AdvisorAndConsultantTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zWOHXg2fZsz">60,000 warrants as compensation for advisor and consultant services, including <span id="xdx_90A_ecustom--WarrantsIssued_pid_uShares_c20210401__20210630__srt--TitleOfIndividualAxis__custom--AdvisorAndConsultantTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zje6x3dL6GH7">50,000 warrants issued to an executive of the Company. The warrants expenses were fair valued at $<span id="xdx_90A_eus-gaap--FairValueAdjustmentOfWarrants_pp0p0_c20210401__20210630__srt--TitleOfIndividualAxis__custom--AdvisorAndConsultantTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zM3hfn9ryrOh">151,897 and was recognized as general and administrative expenses, with a corresponding credit to additional paid-in capital. In addition, <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--AdvisorAndConsultantTwoMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember_zBuMTBAbpbsl">100,236 of warrants previously issued on convertible notes were exercised for cash of $<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_c20210401__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--AdvisorAndConsultantTwoMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember_zb6m4yU4JQZ2">106,250, recognized as a credit to common stock and additional paid in capital respectively. During the three months ended June 30, 2021, one warrant holder provided cash of $40,000 to exercise <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20210630__srt--TitleOfIndividualAxis__custom--OneWarrantHolderMember_zTmnxSXDQn4b" title="Number of warrants exercised">37,736 warrants, which led to 37,736 shares to be issued as at June 30, 2021. Total shares to be issued for warrant exercise requests received but not processed is <span id="xdx_902_ecustom--SharesToBeIssuedDuringPeriodForWarrantExercise_c20210401__20210630__srt--TitleOfIndividualAxis__custom--OneWarrantHolderMember_zYv7W0LsHZh4" title="Shares to be issued during the period for warrant exercise">37,736 as at June 30, 2021. <p id="xdx_899_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zwF3JNyBZHKk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">Warrant issuances, exercises and expirations or cancellations during the three months ended June 30, 2021 and preceding periods resulted in warrants outstanding at the end of those respective periods as follows: SCHEDULE OF WARRANTS OUTSTANDING <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Broker Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Consultant Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Warrants Issued on Conversion of Convertible Notes</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Private Placement Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 25%">As at March 31, 2020</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_uShares_c20200401__20210331__us-gaap--StatementEquityComponentsAxis__custom--BrokerWarrantsMember_ztKdUAc7pKOa" style="width: 12%; text-align: right" title="Warrants outstanding, Beginning balance">321,314</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_uShares_c20200401__20210331__us-gaap--StatementEquityComponentsAxis__custom--ConsultantWarrantsMember_zXIIwfWYoMxi" style="width: 12%; text-align: right" title="Warrants outstanding, Beginning balance">2,049,837</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_uShares_c20200401__20210331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsIssuedOnConversionOfConvertibleNotesMember_zbOCl6pEY4g5" style="width: 12%; text-align: right" title="Warrants outstanding, Beginning balance">2,734,530</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_uShares_c20200401__20210331__us-gaap--StatementEquityComponentsAxis__custom--PrivatePlacementWarrantsMember_zIlpIhEz7NIc" style="width: 12%; text-align: right" title="Warrants outstanding, Beginning balance">1,163,722</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_uShares_c20200401__20210331_zJvSJMvOD934" style="width: 12%; text-align: right" title="Warrants outstanding, Beginning balance">6,269,403</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Less: Expired/cancelled</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_di_c20200401__20210331__us-gaap--StatementEquityComponentsAxis__custom--BrokerWarrantsMember_zNEy5dLDqCWj" style="text-align: right" title="Warrants outstanding, Expired/cancelled">(128,676</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_di_c20200401__20210331__us-gaap--StatementEquityComponentsAxis__custom--ConsultantWarrantsMember_zt92cwpB5xRl" style="text-align: right" title="Warrants outstanding, Expired/cancelled">(271,365</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_di_c20200401__20210331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsIssuedOnConversionOfConvertibleNotesMember_zCGRa4mwdxj4" style="text-align: right" title="Warrants outstanding, Expired/cancelled">(911,510</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_di_c20200401__20210331__us-gaap--StatementEquityComponentsAxis__custom--PrivatePlacementWarrantsMember_z2XsQ20jYjZ9" style="text-align: right" title="Warrants outstanding, Expired/cancelled">(1,163,722</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_di_c20200401__20210331_zxH9Gfijws85" style="text-align: right" title="Warrants outstanding, Expired/cancelled">(2,475,273</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Less: Exercised</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_uShares_c20200401__20210331__us-gaap--StatementEquityComponentsAxis__custom--ConsultantWarrantsMember_zf8Y8sdksRVg" style="text-align: right" title="Warrants outstanding, Exercised">(97,500</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_uShares_c20200401__20210331_zOX3sPWrMgv4" style="text-align: right" title="Warrants outstanding, Exercised">(97,500</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; text-align: left">Add: Issued</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_uShares_c20200401__20210331__us-gaap--StatementEquityComponentsAxis__custom--BrokerWarrantsMember_z0g6wCum3QTa" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants outstanding, Issued">1,065,857</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_uShares_c20200401__20210331__us-gaap--StatementEquityComponentsAxis__custom--ConsultantWarrantsMember_zAmR1Yt2NlZ7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants outstanding, Issued">449,583</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_uShares_c20200401__20210331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsIssuedOnConversionOfConvertibleNotesMember_zUHPIfQWQAyk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants outstanding, Issued">5,631,132</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_uShares_c20200401__20210331__us-gaap--StatementEquityComponentsAxis__custom--PrivatePlacementWarrantsMember_zUWiZWHIZaIj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants outstanding, Issued">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_uShares_c20200401__20210331_zUnm5mz69t63" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants outstanding, Issued">7,146,572</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>As at March 31, 2021</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_uShares_c20210401__20210630__us-gaap--StatementEquityComponentsAxis__custom--BrokerWarrantsMember_zQCbD5nolKi9" style="text-align: right" title="Warrants outstanding, Opening balance">1,258,495</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_uShares_c20210401__20210630__us-gaap--StatementEquityComponentsAxis__custom--ConsultantWarrantsMember_zvxt4yMWAeug" style="text-align: right" title="Warrants outstanding, Opening balance">2,130,555</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_uShares_c20210401__20210630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsIssuedOnConversionOfConvertibleNotesMember_zRlAjav1m1zk" style="text-align: right" title="Warrants outstanding, Opening balance">7,454,152</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_do_uShares_c20210401__20210630__us-gaap--StatementEquityComponentsAxis__custom--PrivatePlacementWarrantsMember_zl0V1HjJkAne" style="text-align: right" title="Warrants outstanding, Ending balance">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_uShares_c20210401__20210630_zVuO8GTnU2le" style="text-align: right" title="Warrants outstanding, Opening balance">10,843,202</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Less: Expired/cancelled</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_pid_di_uShares_c20210401__20210630__us-gaap--StatementEquityComponentsAxis__custom--BrokerWarrantsMember_zixF0IkqFZek" style="text-align: right" title="Warrants outstanding, Expired/cancelled">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_pid_di_uShares_c20210401__20210630__us-gaap--StatementEquityComponentsAxis__custom--ConsultantWarrantsMember_ziklZ7AqbDv6" style="text-align: right" title="Warrants outstanding, Expired/cancelled">(93,750</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_pid_di_uShares_c20210401__20210630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsIssuedOnConversionOfConvertibleNotesMember_zgB4RIZhtGR9" style="text-align: right" title="Warrants outstanding, Expired/cancelled">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_pid_di_uShares_c20210401__20210630__us-gaap--StatementEquityComponentsAxis__custom--PrivatePlacementWarrantsMember_zsbdeND3Dp0f" style="text-align: right" title="Warrants outstanding, Expired/cancelled">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_pid_di_uShares_c20210401__20210630_zSbGJUSuu29h" style="text-align: right" title="Warrants outstanding, Expired/cancelled">(93,750</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Less: Exercised</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"/><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_uShares_c20210401__20210630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsIssuedOnConversionOfConvertibleNotesMember_zw25ivNhGG8f" style="text-align: right" title="Warrants outstanding, Exercised">(137,972</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"/><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_uShares_c20210401__20210630_zm7CObPiTEv9" style="text-align: right" title="Warrants outstanding, Exercised">(137,972</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left">Add: Issued</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_uShares_c20210401__20210630__us-gaap--StatementEquityComponentsAxis__custom--BrokerWarrantsMember_zn2NkEIil8A6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants outstanding, Issued">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_uShares_c20210401__20210630__us-gaap--StatementEquityComponentsAxis__custom--ConsultantWarrantsMember_ztGSOSEHP39l" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants outstanding, Issued">60,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_uShares_c20210401__20210630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsIssuedOnConversionOfConvertibleNotesMember_zETAHeWokGbj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants outstanding, Issued">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_uShares_c20210401__20210630__us-gaap--StatementEquityComponentsAxis__custom--PrivatePlacementWarrantsMember_zr5Jm3G6Ekhb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants outstanding, Issued">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_uShares_c20210401__20210630_zPRvy5az1sU" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants outstanding, Issued">60,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>As at June 30, 2021</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_uShares_c20210401__20210630__us-gaap--StatementEquityComponentsAxis__custom--BrokerWarrantsMember_zlNMgbTCZLJd" style="text-align: right" title="Warrants outstanding, Ending balance">1,258,495</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_uShares_c20210401__20210630__us-gaap--StatementEquityComponentsAxis__custom--ConsultantWarrantsMember_zZm3OdY8uLQg" style="text-align: right" title="Warrants outstanding, Ending balance">2,096,805</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_uShares_c20210401__20210630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsIssuedOnConversionOfConvertibleNotesMember_zcBpgELK14b2" style="text-align: right" title="Warrants outstanding, Ending balance">7,316,180</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_do_uShares_c20210401__20210630__us-gaap--StatementEquityComponentsAxis__custom--PrivatePlacementWarrantsMember_zQFDQZgv7Nuh" style="text-align: right" title="Warrants outstanding, Ending balance">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_uShares_c20210401__20210630_zQJds0nLov47" style="text-align: right" title="Warrants outstanding, Ending balance">10,671,480</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercise Price</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">$<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20210630__us-gaap--StatementEquityComponentsAxis__custom--BrokerWarrantsMember__srt--RangeAxis__srt--MinimumMember_zxNW8hIsMt11" title="Exercise Price">1.06 to $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20210630__us-gaap--StatementEquityComponentsAxis__custom--BrokerWarrantsMember__srt--RangeAxis__srt--MaximumMember_zKbV2a9xosJ5" title="Exercise Price">3.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">$<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20210630__us-gaap--StatementEquityComponentsAxis__custom--ConsultantWarrantsMember__srt--RangeAxis__srt--MinimumMember_zR0ScwtSVHE4" title="Exercise Price">0.48-$<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20210630__us-gaap--StatementEquityComponentsAxis__custom--ConsultantWarrantsMember__srt--RangeAxis__srt--MaximumMember_zpLnoC5Zg983" title="Exercise Price">7.59</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">$<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20210630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsIssuedOnConversionOfConvertibleNoteMember__srt--RangeAxis__srt--MinimumMember_zZlO5yyHyhuj" title="Exercise Price">1.06 to $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20210630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsIssuedOnConversionOfConvertibleNoteMember__srt--RangeAxis__srt--MaximumMember_zeDKOdMk8W8c" title="Exercise Price">2.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expiration Date</td><td> </td> <td style="text-align: left"> </td><td style="text-align: center"><span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_dd_c20210401__20210630__us-gaap--StatementEquityComponentsAxis__custom--BrokerWarrantsMember_zKt9KOFVcdwd" title="Warrant or right, reason for issuance, description">Dec 2021 to Jan 2031</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: center"><span id="xdx_903_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_dd_c20210401__20210630__us-gaap--StatementEquityComponentsAxis__custom--ConsultantWarrantsMember_zMCA1DQpKUc7" title="Warrant or right, reason for issuance, description">Oct 2017 to Mar 2031</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: center"><span id="xdx_907_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_dd_c20210401__20210630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsIssuedOnConversionOfConvertibleNoteMember_zAe5N4mpX7yd" title="Warrant or right, reason for issuance, description">May 2022 to Feb 2024</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> </table> f) Stock-based compensation On February 2, 2016, the Board of Directors of the Company approved the Company’s 2016 Equity Incentive Plan (the “Plan”). The purpose of the Plan is to advance the interests of the Company and its stockholders by providing an incentive to attract, retain and reward persons performing services for the Company and by motivating such persons to contribute to the growth and profitability of the Company. The Plan seeks to achieve this purpose by providing for awards in the form of options, stock appreciation rights, restricted stock purchase rights, restricted stock bonuses, restricted stock units, performance shares, performance units and other stock-based awards. The Plan shall continue in effect until its termination by the board of directors or committee formed by the board; provided, however, that all awards shall be granted, if at all, on or before the day immediately preceding the tenth (10th) anniversary of the effective date. <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms_c20160130__20160202__us-gaap--PlanNameAxis__custom--TwoThousandAndSixteenEquityIncentivePlanMember" title="Plan description">The maximum number of shares of stock that may be issued under the Plan shall be equal to <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_c20160202__us-gaap--PlanNameAxis__custom--TwoThousandAndSixteenEquityIncentivePlanMember_pdd" title="Number of options authorized to issue">3,750,000 shares; provided that the maximum number of shares of stock that may be issued under the Plan pursuant to awards shall automatically and without any further Company or shareholder approval, increase on January 1 of each year for not more than <span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20190401__20200331__us-gaap--PlanNameAxis__custom--TwoThousandAndSixteenEquityIncentivePlanMember__srt--TitleOfIndividualAxis__custom--BoardOfDirectorMember_zV25x6zIgAXj">10 years from the effective date, so the number of shares that may be issued is an amount no greater than 20% of the Company’s outstanding shares of stock and shares of stock underlying any outstanding exchangeable shares as of such January 1; provided further that no such increase shall be effective if it would violate any applicable law or stock exchange rule or regulation, or result in adverse tax consequences to the Company or any participant that would not otherwise result but for the increase. Based on the 2016 Option Plan, the Company is authorized to issue employee options with a <span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190401__20200331__us-gaap--PlanNameAxis__custom--TwoThousandAndSixteenEquityIncentivePlanMember__srt--TitleOfIndividualAxis__custom--BoardOfDirectorMember_zUy6tUjW3NA3">10-year term. On March 31, 2020, the Company’s Board of Directors approved the amendment of certain prior options grants, issued to current employees, previously issued with a <span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200301__20200331__us-gaap--PlanNameAxis__custom--TwoThousandAndSixteenEquityIncentivePlanMember__srt--RangeAxis__srt--MinimumMember_zHsKvSjF5sB6">3-year term, such that the respective options issued under these agreements would have their term extended to <span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200301__20200331__us-gaap--PlanNameAxis__custom--TwoThousandAndSixteenEquityIncentivePlanMember__srt--RangeAxis__srt--MaximumMember_z7we6lAqhjG1">10 years. The Company revalued these options using a lattice model with an expected life of <span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190401__20200331__us-gaap--PlanNameAxis__custom--TwoThousandAndSixteenEquityIncentivePlanMember__srt--TitleOfIndividualAxis__custom--BoardOfDirectorMember_zSxztJkwpTbe">10 years, risk free rates of <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20200301__20200331__us-gaap--PlanNameAxis__custom--TwoThousandAndSixteenEquityIncentivePlanMember__srt--RangeAxis__srt--MinimumMember_zN4ECDTzznHg" title="Risk free rate">0.46% to <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20200301__20200331__us-gaap--PlanNameAxis__custom--TwoThousandAndSixteenEquityIncentivePlanMember__srt--RangeAxis__srt--MaximumMember_zY7CUiSqfvY5" title="Risk free rate">0.75%, stock price of $0.974 and expected volatility of <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_uPure_c20190401__20200331__us-gaap--PlanNameAxis__custom--TwoThousandAndSixteenEquityIncentivePlanMember__srt--TitleOfIndividualAxis__custom--BoardOfDirectorMember_z2QNtMR1zFvd" title="Expected volatility">132.2%, in order to recognize the additional expense associated with the longer term and recognized a one-time charge of $<span id="xdx_903_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensationGross_c20190401__20200331__us-gaap--PlanNameAxis__custom--TwoThousandAndSixteenEquityIncentivePlanMember__srt--TitleOfIndividualAxis__custom--BoardOfDirectorMember_pp0p0" title="Number of common stock compensation for services, value">1,600,515 in share-based compensation, with a corresponding adjustment to adjusted paid in capital. During the year ended March 31, 2021, the Company granted <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20200401__20210331__us-gaap--PlanNameAxis__custom--TwoThousandAndSixteenEquityIncentivePlanMember_zqKmT7BMP0u1" title="Number of options granted">2,610,647 stock options with a weighted average remaining contractual life of <span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20190401__20200331__us-gaap--PlanNameAxis__custom--TwoThousandAndSixteenEquityIncentivePlanMember_z09sJMmMpWbl">8.7 years. The Company recorded stock-based compensation of $790,535 in connection with ESOP 2016 Plan under general and administrative expenses with corresponding credit to additional paid in capital. During the three months ended June 30, 2021, the Company granted <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20210401__20210630__us-gaap--PlanNameAxis__custom--TwoThousandAndSixteenEquityIncentivePlanMember_zSEvCL5KWfkb">170,532 of options with a weighted average remaining contractual life of <span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210401__20210630__us-gaap--PlanNameAxis__custom--TwoThousandAndSixteenEquityIncentivePlanMember_z2N6GVhpMpUk">9.3 years. The Company recorded stock-based compensation of $155,851 in connection with ESOP 2016 Plan (June 30, 2020 - $<span id="xdx_906_eus-gaap--AdditionalPaidInCapital_iI_pp0p0_c20210630__us-gaap--PlanNameAxis__custom--TwoThousandAndSixteenEquityIncentivePlanMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zaGTCkqVRBKk">232,519), under general and administrative expenses with corresponding credit to additional paid in capital. <p id="xdx_891_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zqAnyylBkoCk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">The following table summarizes the stock option activities of the Company to June 30, 2021: SCHEDULE OF STOCK OPTION ACTIVITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of options</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted average exercise price ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Outstanding as of March 31, 2018</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_uShares_c20170401__20180331_zaCqUID6bgPd" style="text-align: right" title="Number of options outstanding, Exercised">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20170401__20180331_zdL5pFK46wYg" style="text-align: right" title="Weighted average exercise price, Beginning balance">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Granted</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20170401__20180331_zPKi2rRRKWV6" style="width: 16%; text-align: right" title="Number of options outstanding, Granted">4,147,498</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20170401__20180331_zf5H0g4TLX5l" style="width: 16%; text-align: right" title="Weighted average exercise price, Granted">3.2306</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_uShares_c20170401__20180331_zZmWMD17L8q4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of options outstanding, Exercised">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20170401__20180331_zIPXQ8lutW7l" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, Exercised">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; padding-bottom: 1.5pt">Outstanding as of March 31, 2018</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_uShares_c20180401__20190331_zxUaMvtaJSc1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Number of options outstanding, Beginning balance">4,147,498</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20180401__20190331_ziAsGwT0vVeb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Weighted average exercise price, Ending balance">3.2306</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20180401__20190331_zHF1V7rAMgeh" style="text-align: right" title="Number of options outstanding, Granted">270,521</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20180401__20190331_zM1Ave6foE69" style="text-align: right" title="Weighted average exercise price, Granted">1.8096</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_uShares_c20180401__20190331_zMMkAKqFq8Zg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of options outstanding, Exercised">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20180401__20190331_zNjn79FRiV4c" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, Exercised">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold">Outstanding as of March 31, 2019</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_uShares_c20190401__20200331_zaBIfjeuSFBg" style="font-weight: bold; text-align: right" title="Number of options outstanding, Beginning balance">4,418,019</td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20190401__20200331_z2Jh656CQBtb" style="font-weight: bold; text-align: right" title="Weighted average exercise price, Beginning balance">3.1436</td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20190401__20200331_zFHLoL2mz1F1" style="text-align: right" title="Number of options outstanding, Granted">88,100</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20190401__20200331_zAJ5WXKhXPE7" style="text-align: right" title="Weighted average exercise price, Granted">0.7763</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Expired</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_uShares_c20190401__20200331_zQJLnnBBNTlb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of options outstanding, Expired">(112,509</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20190401__20200331_zgTkVOt2pcx9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, Expired">2.723</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Outstanding as of March 31, 2020</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_uShares_c20200401__20210331_zrgn5gKXYcO7" style="font-weight: bold; text-align: right" title="Number of options outstanding, Beginning balance">4,393,610</td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20200401__20210331_zhThAGOm30ib" style="font-weight: bold; text-align: right" title="Weighted average exercise price, Beginning balance">3.1069</td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20200401__20210331_zLAzXvDag1Qe" style="text-align: right" title="Number of options outstanding, Granted">2,610,647</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20200401__20210331_zLNcl1dGuxcb" style="text-align: right" title="Weighted average exercise price, Granted">1.0072</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_uShares_c20200401__20210331_zZ9k8eoeyZZ9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of options outstanding, Exercised">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20200401__20210331_zXLMfn96cFsc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, Exercised">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold">Outstanding as of March 31, 2021</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_uShares_c20210401__20210630_zElwAOtVjgc4" style="font-weight: bold; text-align: right" title="Number of options outstanding, Beginning balance">7,004,256</td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20210401__20210630_zkOHO8XHulb6" style="font-weight: bold; text-align: right" title="Weighted average exercise price, Beginning balance">2.3268</td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20210401__20210630_ze58O0fb8hfe" style="text-align: right" title="Number of options outstanding, Granted">170,532</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20210401__20210630_zgbfZUYgibAf" style="text-align: right" title="Weighted average exercise price, Granted">1.7931</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_uShares_c20210401__20210630_zmIrCwYi7Ns8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of options outstanding, Exercised">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20210401__20210630_zCS74tg1tFS1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, Exercised">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; padding-bottom: 1.5pt">Outstanding as of June 30, 2021</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_uShares_c20210401__20210630_zYyMo41AAII4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Number of options outstanding, Ending balance">7,174,788</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20210401__20210630_zDFy4jplfNY8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Weighted average exercise price, Ending balance">2.3141</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td></tr> </table> <p id="xdx_89B_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zkCcmP6KiGR8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">The fair value of each option granted is estimated at the time of grant using the Black Scholes model using the following assumptions, for each of the respective fiscal year: SCHEDULE OF FAIR VALUE OF OPTION GRANTED USING VALUATION ASSUMPTIONS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2022</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2021</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2020</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center; font-weight: bold">2019</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%">Exercise price ($) </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">0.74 – 3.15</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_uUSDPShares_c20210331__srt--RangeAxis__srt--MinimumMember_zW7QoaScqUr8" title="Exercise price">0.74-<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_uUSDPShares_c20210331__srt--RangeAxis__srt--MaximumMember_zfZH6RwVNHSl" title="Exercise price">2.89</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_uUSDPShares_c20200331__srt--RangeAxis__srt--MinimumMember_zS6F10ahpeji" title="Exercise price">1.40-<span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_uUSDPShares_c20200331__srt--RangeAxis__srt--MaximumMember_zSFIw4ZnHTxh" title="Exercise price">2.00</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="vertical-align: bottom; width: 1%; text-align: right"> </td><td style="vertical-align: bottom; width: 12%; text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_uUSDPShares_c20190331__srt--RangeAxis__srt--MinimumMember_z0VcfNIYLowc" title="Exercise price">1.40-<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_uUSDPShares_c20190331__srt--RangeAxis__srt--MaximumMember_z7hJ1mLo14x5" title="Exercise price">2.00</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Risk free interest rate (%) </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.30 – 1.70</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_uPure_c20200401__20210331_zFan8Mfn3s06" title="Risk free interest rate, Minimum">0.18 – <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20200401__20210331_zmNyEyU7Y8X2" title="Risk free interest rate, Maximum">1.72</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20190401__20200331_zpXZo5IrVNz9" title="Risk free interest rate, Minimum">0.52-<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20190401__20200331_zjVn4Funf2hk" title="Risk free interest rate, Maximum">2.81</td><td style="text-align: left"> </td><td> </td> <td style="vertical-align: bottom; text-align: right"> </td><td style="vertical-align: bottom; text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20180401__20190331_z6OHUdGSlpQ6" title="Risk free interest rate, Minimum">2.27-<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20180401__20190331_zVhPTrqpJsj9" title="Risk free interest rate, Maximum">2.81</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected term (Years) </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2.0 – 10.0</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pp0d_dtY_c20200401__20210331__srt--RangeAxis__srt--MinimumMember_zi9j0B8L1I48" title="Expected term (Years)">2.0 – <span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200401__20210331__srt--RangeAxis__srt--MaximumMember_z1ZbnJiWdpm" title="Expected term (Years)">10.0</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190401__20200331__srt--RangeAxis__srt--MinimumMember_zQExYbypRyC9" title="Expected term (Years)">2.0-<span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190401__20200331__srt--RangeAxis__srt--MaximumMember_zwk86779dcOc" title="Expected term (Years)">3.0</td><td style="text-align: left"> </td><td> </td> <td style="vertical-align: bottom; text-align: right"> </td><td style="vertical-align: bottom; text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20180401__20190331__srt--RangeAxis__srt--MinimumMember_zfKras5S4HMj" title="Expected term (Years)">2.0-<span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20180401__20190331__srt--RangeAxis__srt--MaximumMember_zNiAg9DHHqA3" title="Expected term (Years)">3.0</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected volatility (%) </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">107.6 – 129.9</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="vertical-align: bottom; text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20200401__20210331_zR31HUElGHG" title="Expected volatility, Minimum">106.8 – <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20200401__20210331_zOeo2sD43PCa" title="Expected volatility, Maximum">129.9 </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20190401__20200331_zH1CA1SQKEwh" title="Expected volatility, Minimum">97.8-<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20190401__20200331_zG1Ex5HpSnZf" title="Expected volatility, Maximum">141.1</td><td style="text-align: left"> </td><td> </td> <td style="vertical-align: bottom; text-align: right"> </td><td style="vertical-align: bottom; text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20180401__20190331_zDKOc7Sxwle6" title="Expected volatility, Minimum">97.8-<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20180401__20190331_zDl1IXy7Kg11" title="Expected volatility, Maximum">141.1</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected dividend yield (%) </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.00</td><td style="text-align: left"> </td><td> </td> <td style="vertical-align: bottom; text-align: right"> </td><td style="vertical-align: bottom; text-align: right">0.00</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Fair value of option ($) </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.59 – 2.14</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.72 - 1.72</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.76</td><td style="text-align: left"> </td><td> </td> <td style="vertical-align: bottom; text-align: right"> </td><td style="vertical-align: bottom; text-align: right">0.588</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected forfeiture (attrition) rate (%) </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.00</td><td style="text-align: left"> </td><td> </td> <td style="vertical-align: bottom; text-align: right"> </td><td style="vertical-align: bottom; text-align: right">0.00</td><td style="text-align: left"> </td></tr> </table>

125000000

0.001

10000000

0.001

20000

0.001

39316782

39014942

37850064

36124964

1466718

2889978

0.001

20000

8045

1.197 shares of its common stock in exchange for each common share of iMedical held by the iMedical shareholders who in general terms, are not residents of Canada 1.197 Exchangeable Shares in the capital of Exchangeco in exchange for each common share of iMedical held. 1.197 economically equivalent replacement options with an inverse adjustment to the exercise price of the replacement option to reflect the exchange ratio of approximately 1.197:1; 1.197 shares of the common stock of the Company for each warrant, with an inverse adjustment to the exercise price of the warrants to reflect the exchange ratio of approximately 1.197:1 1.197 shares of the common stock of the Company for each advisor warrant, with an inverse adjustment to the exercise price of the Advisor Warrants to reflect the exchange ratio of approximately 1.197:1;

The outstanding 11% secured convertible promissory notes of iMedical were adjusted, in accordance with the adjustment provisions thereof, as and from closing, so as to permit the holders to convert (and in some circumstances permit the Company to force the conversion of) the convertible promissory notes into shares of the common stock of the Company at a 25% discount to purchase price per share in Biotricity’s next offering

0.25

962148

257927

602969

180000

733085

18402

1011286

739000

225284

47002

1076561

38460

103375

1900042

898084

183202

345676

1642049

1157500

403108

81441

479760

1190502

28213

1423260

18402

345676

1190502

55493

97500

67941

449583

275801

788806

P3Y

P10Y

288806

464971

1065857

5631132

60000

50000

151897

100236

106250

40000

37736

<p id="xdx_899_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zwF3JNyBZHKk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">Warrant issuances, exercises and expirations or cancellations during the three months ended June 30, 2021 and preceding periods resulted in warrants outstanding at the end of those respective periods as follows: SCHEDULE OF WARRANTS OUTSTANDING <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Broker Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Consultant Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Warrants Issued on Conversion of Convertible Notes</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Private Placement Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 25%">As at March 31, 2020</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_uShares_c20200401__20210331__us-gaap--StatementEquityComponentsAxis__custom--BrokerWarrantsMember_ztKdUAc7pKOa" style="width: 12%; text-align: right" title="Warrants outstanding, Beginning balance">321,314</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_uShares_c20200401__20210331__us-gaap--StatementEquityComponentsAxis__custom--ConsultantWarrantsMember_zXIIwfWYoMxi" style="width: 12%; text-align: right" title="Warrants outstanding, Beginning balance">2,049,837</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_uShares_c20200401__20210331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsIssuedOnConversionOfConvertibleNotesMember_zbOCl6pEY4g5" style="width: 12%; text-align: right" title="Warrants outstanding, Beginning balance">2,734,530</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_uShares_c20200401__20210331__us-gaap--StatementEquityComponentsAxis__custom--PrivatePlacementWarrantsMember_zIlpIhEz7NIc" style="width: 12%; text-align: right" title="Warrants outstanding, Beginning balance">1,163,722</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_uShares_c20200401__20210331_zJvSJMvOD934" style="width: 12%; text-align: right" title="Warrants outstanding, Beginning balance">6,269,403</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Less: Expired/cancelled</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_di_c20200401__20210331__us-gaap--StatementEquityComponentsAxis__custom--BrokerWarrantsMember_zNEy5dLDqCWj" style="text-align: right" title="Warrants outstanding, Expired/cancelled">(128,676</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_di_c20200401__20210331__us-gaap--StatementEquityComponentsAxis__custom--ConsultantWarrantsMember_zt92cwpB5xRl" style="text-align: right" title="Warrants outstanding, Expired/cancelled">(271,365</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_di_c20200401__20210331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsIssuedOnConversionOfConvertibleNotesMember_zCGRa4mwdxj4" style="text-align: right" title="Warrants outstanding, Expired/cancelled">(911,510</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_di_c20200401__20210331__us-gaap--StatementEquityComponentsAxis__custom--PrivatePlacementWarrantsMember_z2XsQ20jYjZ9" style="text-align: right" title="Warrants outstanding, Expired/cancelled">(1,163,722</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_di_c20200401__20210331_zxH9Gfijws85" style="text-align: right" title="Warrants outstanding, Expired/cancelled">(2,475,273</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Less: Exercised</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_uShares_c20200401__20210331__us-gaap--StatementEquityComponentsAxis__custom--ConsultantWarrantsMember_zf8Y8sdksRVg" style="text-align: right" title="Warrants outstanding, Exercised">(97,500</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_uShares_c20200401__20210331_zOX3sPWrMgv4" style="text-align: right" title="Warrants outstanding, Exercised">(97,500</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; text-align: left">Add: Issued</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_uShares_c20200401__20210331__us-gaap--StatementEquityComponentsAxis__custom--BrokerWarrantsMember_z0g6wCum3QTa" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants outstanding, Issued">1,065,857</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_uShares_c20200401__20210331__us-gaap--StatementEquityComponentsAxis__custom--ConsultantWarrantsMember_zAmR1Yt2NlZ7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants outstanding, Issued">449,583</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_uShares_c20200401__20210331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsIssuedOnConversionOfConvertibleNotesMember_zUHPIfQWQAyk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants outstanding, Issued">5,631,132</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_uShares_c20200401__20210331__us-gaap--StatementEquityComponentsAxis__custom--PrivatePlacementWarrantsMember_zUWiZWHIZaIj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants outstanding, Issued">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_uShares_c20200401__20210331_zUnm5mz69t63" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants outstanding, Issued">7,146,572</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>As at March 31, 2021</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_uShares_c20210401__20210630__us-gaap--StatementEquityComponentsAxis__custom--BrokerWarrantsMember_zQCbD5nolKi9" style="text-align: right" title="Warrants outstanding, Opening balance">1,258,495</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_uShares_c20210401__20210630__us-gaap--StatementEquityComponentsAxis__custom--ConsultantWarrantsMember_zvxt4yMWAeug" style="text-align: right" title="Warrants outstanding, Opening balance">2,130,555</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_uShares_c20210401__20210630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsIssuedOnConversionOfConvertibleNotesMember_zRlAjav1m1zk" style="text-align: right" title="Warrants outstanding, Opening balance">7,454,152</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_do_uShares_c20210401__20210630__us-gaap--StatementEquityComponentsAxis__custom--PrivatePlacementWarrantsMember_zl0V1HjJkAne" style="text-align: right" title="Warrants outstanding, Ending balance">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_uShares_c20210401__20210630_zVuO8GTnU2le" style="text-align: right" title="Warrants outstanding, Opening balance">10,843,202</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Less: Expired/cancelled</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_pid_di_uShares_c20210401__20210630__us-gaap--StatementEquityComponentsAxis__custom--BrokerWarrantsMember_zixF0IkqFZek" style="text-align: right" title="Warrants outstanding, Expired/cancelled">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_pid_di_uShares_c20210401__20210630__us-gaap--StatementEquityComponentsAxis__custom--ConsultantWarrantsMember_ziklZ7AqbDv6" style="text-align: right" title="Warrants outstanding, Expired/cancelled">(93,750</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_pid_di_uShares_c20210401__20210630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsIssuedOnConversionOfConvertibleNotesMember_zgB4RIZhtGR9" style="text-align: right" title="Warrants outstanding, Expired/cancelled">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_pid_di_uShares_c20210401__20210630__us-gaap--StatementEquityComponentsAxis__custom--PrivatePlacementWarrantsMember_zsbdeND3Dp0f" style="text-align: right" title="Warrants outstanding, Expired/cancelled">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_pid_di_uShares_c20210401__20210630_zSbGJUSuu29h" style="text-align: right" title="Warrants outstanding, Expired/cancelled">(93,750</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Less: Exercised</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"/><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_uShares_c20210401__20210630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsIssuedOnConversionOfConvertibleNotesMember_zw25ivNhGG8f" style="text-align: right" title="Warrants outstanding, Exercised">(137,972</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"/><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_uShares_c20210401__20210630_zm7CObPiTEv9" style="text-align: right" title="Warrants outstanding, Exercised">(137,972</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left">Add: Issued</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_uShares_c20210401__20210630__us-gaap--StatementEquityComponentsAxis__custom--BrokerWarrantsMember_zn2NkEIil8A6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants outstanding, Issued">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_uShares_c20210401__20210630__us-gaap--StatementEquityComponentsAxis__custom--ConsultantWarrantsMember_ztGSOSEHP39l" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants outstanding, Issued">60,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_uShares_c20210401__20210630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsIssuedOnConversionOfConvertibleNotesMember_zETAHeWokGbj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants outstanding, Issued">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_uShares_c20210401__20210630__us-gaap--StatementEquityComponentsAxis__custom--PrivatePlacementWarrantsMember_zr5Jm3G6Ekhb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants outstanding, Issued">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_uShares_c20210401__20210630_zPRvy5az1sU" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants outstanding, Issued">60,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>As at June 30, 2021</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_uShares_c20210401__20210630__us-gaap--StatementEquityComponentsAxis__custom--BrokerWarrantsMember_zlNMgbTCZLJd" style="text-align: right" title="Warrants outstanding, Ending balance">1,258,495</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_uShares_c20210401__20210630__us-gaap--StatementEquityComponentsAxis__custom--ConsultantWarrantsMember_zZm3OdY8uLQg" style="text-align: right" title="Warrants outstanding, Ending balance">2,096,805</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_uShares_c20210401__20210630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsIssuedOnConversionOfConvertibleNotesMember_zcBpgELK14b2" style="text-align: right" title="Warrants outstanding, Ending balance">7,316,180</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_do_uShares_c20210401__20210630__us-gaap--StatementEquityComponentsAxis__custom--PrivatePlacementWarrantsMember_zQFDQZgv7Nuh" style="text-align: right" title="Warrants outstanding, Ending balance">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_uShares_c20210401__20210630_zQJds0nLov47" style="text-align: right" title="Warrants outstanding, Ending balance">10,671,480</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercise Price</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">$<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20210630__us-gaap--StatementEquityComponentsAxis__custom--BrokerWarrantsMember__srt--RangeAxis__srt--MinimumMember_zxNW8hIsMt11" title="Exercise Price">1.06 to $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20210630__us-gaap--StatementEquityComponentsAxis__custom--BrokerWarrantsMember__srt--RangeAxis__srt--MaximumMember_zKbV2a9xosJ5" title="Exercise Price">3.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">$<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20210630__us-gaap--StatementEquityComponentsAxis__custom--ConsultantWarrantsMember__srt--RangeAxis__srt--MinimumMember_zR0ScwtSVHE4" title="Exercise Price">0.48-$<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20210630__us-gaap--StatementEquityComponentsAxis__custom--ConsultantWarrantsMember__srt--RangeAxis__srt--MaximumMember_zpLnoC5Zg983" title="Exercise Price">7.59</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">$<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20210630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsIssuedOnConversionOfConvertibleNoteMember__srt--RangeAxis__srt--MinimumMember_zZlO5yyHyhuj" title="Exercise Price">1.06 to $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20210630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsIssuedOnConversionOfConvertibleNoteMember__srt--RangeAxis__srt--MaximumMember_zeDKOdMk8W8c" title="Exercise Price">2.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expiration Date</td><td> </td> <td style="text-align: left"> </td><td style="text-align: center"><span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_dd_c20210401__20210630__us-gaap--StatementEquityComponentsAxis__custom--BrokerWarrantsMember_zKt9KOFVcdwd" title="Warrant or right, reason for issuance, description">Dec 2021 to Jan 2031</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: center"><span id="xdx_903_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_dd_c20210401__20210630__us-gaap--StatementEquityComponentsAxis__custom--ConsultantWarrantsMember_zMCA1DQpKUc7" title="Warrant or right, reason for issuance, description">Oct 2017 to Mar 2031</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: center"><span id="xdx_907_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_dd_c20210401__20210630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsIssuedOnConversionOfConvertibleNoteMember_zAe5N4mpX7yd" title="Warrant or right, reason for issuance, description">May 2022 to Feb 2024</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> </table>

321314

2049837

2734530

1163722

6269403

128676

271365

911510

1163722

2475273

97500

1065857

449583

5631132

7146572

1258495

2130555

7454152

10843202

93750

137972

60000

1258495

2096805

7316180

10671480

1.06

3.00

0.48

7.59

1.06

2.00

Dec 2021 to Jan 2031

Oct 2017 to Mar 2031

May 2022 to Feb 2024

The maximum number of shares of stock that may be issued under the Plan shall be equal to 3,750,000 shares; provided that the maximum number of shares of stock that may be issued under the Plan pursuant to awards shall automatically and without any further Company or shareholder approval, increase on January 1 of each year for not more than 10 years from the effective date, so the number of shares that may be issued is an amount no greater than 20% of the Company’s outstanding shares of stock and shares of stock underlying any outstanding exchangeable shares as of such January 1; provided further that no such increase shall be effective if it would violate any applicable law or stock exchange rule or regulation, or result in adverse tax consequences to the Company or any participant that would not otherwise result but for the increase.

3750000

P10Y

P3Y

P10Y

0.0046

0.0075

0.974

1.322

1600515

2610647

P8Y8M12D

790535

170532

P9Y3M18D

155851

232519

<p id="xdx_891_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zqAnyylBkoCk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">The following table summarizes the stock option activities of the Company to June 30, 2021: SCHEDULE OF STOCK OPTION ACTIVITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of options</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted average exercise price ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Outstanding as of March 31, 2018</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_uShares_c20170401__20180331_zaCqUID6bgPd" style="text-align: right" title="Number of options outstanding, Exercised">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20170401__20180331_zdL5pFK46wYg" style="text-align: right" title="Weighted average exercise price, Beginning balance">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Granted</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20170401__20180331_zPKi2rRRKWV6" style="width: 16%; text-align: right" title="Number of options outstanding, Granted">4,147,498</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20170401__20180331_zf5H0g4TLX5l" style="width: 16%; text-align: right" title="Weighted average exercise price, Granted">3.2306</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_uShares_c20170401__20180331_zZmWMD17L8q4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of options outstanding, Exercised">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20170401__20180331_zIPXQ8lutW7l" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, Exercised">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; padding-bottom: 1.5pt">Outstanding as of March 31, 2018</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_uShares_c20180401__20190331_zxUaMvtaJSc1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Number of options outstanding, Beginning balance">4,147,498</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20180401__20190331_ziAsGwT0vVeb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Weighted average exercise price, Ending balance">3.2306</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20180401__20190331_zHF1V7rAMgeh" style="text-align: right" title="Number of options outstanding, Granted">270,521</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20180401__20190331_zM1Ave6foE69" style="text-align: right" title="Weighted average exercise price, Granted">1.8096</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_uShares_c20180401__20190331_zMMkAKqFq8Zg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of options outstanding, Exercised">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20180401__20190331_zNjn79FRiV4c" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, Exercised">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold">Outstanding as of March 31, 2019</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_uShares_c20190401__20200331_zaBIfjeuSFBg" style="font-weight: bold; text-align: right" title="Number of options outstanding, Beginning balance">4,418,019</td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20190401__20200331_z2Jh656CQBtb" style="font-weight: bold; text-align: right" title="Weighted average exercise price, Beginning balance">3.1436</td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20190401__20200331_zFHLoL2mz1F1" style="text-align: right" title="Number of options outstanding, Granted">88,100</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20190401__20200331_zAJ5WXKhXPE7" style="text-align: right" title="Weighted average exercise price, Granted">0.7763</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Expired</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_uShares_c20190401__20200331_zQJLnnBBNTlb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of options outstanding, Expired">(112,509</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20190401__20200331_zgTkVOt2pcx9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, Expired">2.723</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Outstanding as of March 31, 2020</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_uShares_c20200401__20210331_zrgn5gKXYcO7" style="font-weight: bold; text-align: right" title="Number of options outstanding, Beginning balance">4,393,610</td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20200401__20210331_zhThAGOm30ib" style="font-weight: bold; text-align: right" title="Weighted average exercise price, Beginning balance">3.1069</td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20200401__20210331_zLAzXvDag1Qe" style="text-align: right" title="Number of options outstanding, Granted">2,610,647</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20200401__20210331_zLNcl1dGuxcb" style="text-align: right" title="Weighted average exercise price, Granted">1.0072</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_uShares_c20200401__20210331_zZ9k8eoeyZZ9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of options outstanding, Exercised">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20200401__20210331_zXLMfn96cFsc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, Exercised">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold">Outstanding as of March 31, 2021</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_uShares_c20210401__20210630_zElwAOtVjgc4" style="font-weight: bold; text-align: right" title="Number of options outstanding, Beginning balance">7,004,256</td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20210401__20210630_zkOHO8XHulb6" style="font-weight: bold; text-align: right" title="Weighted average exercise price, Beginning balance">2.3268</td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20210401__20210630_ze58O0fb8hfe" style="text-align: right" title="Number of options outstanding, Granted">170,532</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20210401__20210630_zgbfZUYgibAf" style="text-align: right" title="Weighted average exercise price, Granted">1.7931</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_uShares_c20210401__20210630_zmIrCwYi7Ns8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of options outstanding, Exercised">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20210401__20210630_zCS74tg1tFS1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, Exercised">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; padding-bottom: 1.5pt">Outstanding as of June 30, 2021</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_uShares_c20210401__20210630_zYyMo41AAII4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Number of options outstanding, Ending balance">7,174,788</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20210401__20210630_zDFy4jplfNY8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Weighted average exercise price, Ending balance">2.3141</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td></tr> </table>

4147498

3.2306

4147498

3.2306

270521

1.8096

4418019

3.1436

88100

0.7763

112509

2.723

4393610

3.1069

2610647

1.0072

7004256

2.3268

170532

1.7931

7174788

2.3141

<p id="xdx_89B_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zkCcmP6KiGR8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">The fair value of each option granted is estimated at the time of grant using the Black Scholes model using the following assumptions, for each of the respective fiscal year: SCHEDULE OF FAIR VALUE OF OPTION GRANTED USING VALUATION ASSUMPTIONS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2022</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2021</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2020</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center; font-weight: bold">2019</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%">Exercise price ($) </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">0.74 – 3.15</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_uUSDPShares_c20210331__srt--RangeAxis__srt--MinimumMember_zW7QoaScqUr8" title="Exercise price">0.74-<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_uUSDPShares_c20210331__srt--RangeAxis__srt--MaximumMember_zfZH6RwVNHSl" title="Exercise price">2.89</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_uUSDPShares_c20200331__srt--RangeAxis__srt--MinimumMember_zS6F10ahpeji" title="Exercise price">1.40-<span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_uUSDPShares_c20200331__srt--RangeAxis__srt--MaximumMember_zSFIw4ZnHTxh" title="Exercise price">2.00</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="vertical-align: bottom; width: 1%; text-align: right"> </td><td style="vertical-align: bottom; width: 12%; text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_uUSDPShares_c20190331__srt--RangeAxis__srt--MinimumMember_z0VcfNIYLowc" title="Exercise price">1.40-<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_uUSDPShares_c20190331__srt--RangeAxis__srt--MaximumMember_z7hJ1mLo14x5" title="Exercise price">2.00</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Risk free interest rate (%) </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.30 – 1.70</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_uPure_c20200401__20210331_zFan8Mfn3s06" title="Risk free interest rate, Minimum">0.18 – <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20200401__20210331_zmNyEyU7Y8X2" title="Risk free interest rate, Maximum">1.72</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20190401__20200331_zpXZo5IrVNz9" title="Risk free interest rate, Minimum">0.52-<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20190401__20200331_zjVn4Funf2hk" title="Risk free interest rate, Maximum">2.81</td><td style="text-align: left"> </td><td> </td> <td style="vertical-align: bottom; text-align: right"> </td><td style="vertical-align: bottom; text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20180401__20190331_z6OHUdGSlpQ6" title="Risk free interest rate, Minimum">2.27-<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20180401__20190331_zVhPTrqpJsj9" title="Risk free interest rate, Maximum">2.81</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected term (Years) </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2.0 – 10.0</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pp0d_dtY_c20200401__20210331__srt--RangeAxis__srt--MinimumMember_zi9j0B8L1I48" title="Expected term (Years)">2.0 – <span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200401__20210331__srt--RangeAxis__srt--MaximumMember_z1ZbnJiWdpm" title="Expected term (Years)">10.0</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190401__20200331__srt--RangeAxis__srt--MinimumMember_zQExYbypRyC9" title="Expected term (Years)">2.0-<span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190401__20200331__srt--RangeAxis__srt--MaximumMember_zwk86779dcOc" title="Expected term (Years)">3.0</td><td style="text-align: left"> </td><td> </td> <td style="vertical-align: bottom; text-align: right"> </td><td style="vertical-align: bottom; text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20180401__20190331__srt--RangeAxis__srt--MinimumMember_zfKras5S4HMj" title="Expected term (Years)">2.0-<span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20180401__20190331__srt--RangeAxis__srt--MaximumMember_zNiAg9DHHqA3" title="Expected term (Years)">3.0</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected volatility (%) </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">107.6 – 129.9</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="vertical-align: bottom; text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20200401__20210331_zR31HUElGHG" title="Expected volatility, Minimum">106.8 – <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20200401__20210331_zOeo2sD43PCa" title="Expected volatility, Maximum">129.9 </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20190401__20200331_zH1CA1SQKEwh" title="Expected volatility, Minimum">97.8-<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20190401__20200331_zG1Ex5HpSnZf" title="Expected volatility, Maximum">141.1</td><td style="text-align: left"> </td><td> </td> <td style="vertical-align: bottom; text-align: right"> </td><td style="vertical-align: bottom; text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20180401__20190331_zDKOc7Sxwle6" title="Expected volatility, Minimum">97.8-<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20180401__20190331_zDl1IXy7Kg11" title="Expected volatility, Maximum">141.1</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected dividend yield (%) </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.00</td><td style="text-align: left"> </td><td> </td> <td style="vertical-align: bottom; text-align: right"> </td><td style="vertical-align: bottom; text-align: right">0.00</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Fair value of option ($) </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.59 – 2.14</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.72 - 1.72</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.76</td><td style="text-align: left"> </td><td> </td> <td style="vertical-align: bottom; text-align: right"> </td><td style="vertical-align: bottom; text-align: right">0.588</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected forfeiture (attrition) rate (%) </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.00</td><td style="text-align: left"> </td><td> </td> <td style="vertical-align: bottom; text-align: right"> </td><td style="vertical-align: bottom; text-align: right">0.00</td><td style="text-align: left"> </td></tr> </table>

0.74

3.15

0.74

2.89

1.40

2.00

1.40

2.00

0.30

0.0170

0.18

0.0172

0.0052

0.0281

0.0227

0.0281

P2Y

P10Y

P2Y

P10Y

P2Y

P3Y

P2Y

P3Y

1.076

1.299

1.068

1.299

0.978

1.411

0.978

1.411

0.0000

0.59

2.14

0.72

1.72

0.76

0.588

0.0000 0.0000 0.0000 0.0000

9. LEASE The Company has one operating lease primarily for office and administration. The Company adopted ASC 842 – Leases using the modified retrospective cumulative catch-up approach beginning on April 1, 2019. Under this approach, the Company did not restate its comparative amounts and recognized a right-of-use asset equal to the present value of the future lease payments. The Company elected to apply the practical expedient to only transition contracts which were previously identified as leases and elected to not recognize right-of-use assets and lease obligations for leases of low value assets. When measuring the lease obligations, the Company discounted lease payments using its incremental borrowing rate. The weighted-average-rate applied is 10%. <p id="xdx_895_eus-gaap--OperatingLeasesOfLesseeDisclosureTextBlock_zAqU7mdNVK91" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"> SCHEDULE OF OPERATING LEASES OBLIGATIONS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">$</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">Operating lease right-of-use asset - initial recognition</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_980_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0_c20210331__us-gaap--AdjustmentsForNewAccountingPronouncementsAxis__us-gaap--AccountingStandardsUpdate201902Member_zZ7U9OYYKbc7" style="width: 16%; text-align: right" title="Operating lease right-of-use asset - initial recognition">413,236</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Amortization</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--OperatingLeaseRightOfUseAssetAmortizationExpense_pp0p0_c20210401__20210630__us-gaap--AdjustmentsForNewAccountingPronouncementsAxis__us-gaap--AccountingStandardsUpdate201902Member_zminqs4JABng" style="border-bottom: Black 1.5pt solid; text-align: right" title="Amortization">(413,236</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance at June 30, 2021</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0_c20210630__us-gaap--AdjustmentsForNewAccountingPronouncementsAxis__us-gaap--AccountingStandardsUpdate201902Member_ziVzK594moEj" style="border-bottom: Black 2.5pt double; text-align: right" title="Operating lease right-of-use asset">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Operating lease obligation - initial recognition</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--OperatingLeaseLiability_iI_pp0p0_c20210331__us-gaap--AdjustmentsForNewAccountingPronouncementsAxis__us-gaap--AccountingStandardsUpdate201902Member_zDNFgvki0A3g" style="text-align: right" title="Operating lease obligation - initial recognition">413,236</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Repayment and interest accretion</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_ecustom--OperatingLeaseRepaymentAndInterestAccretion_pp0p0_c20210401__20210630__us-gaap--AdjustmentsForNewAccountingPronouncementsAxis__us-gaap--AccountingStandardsUpdate201902Member_zrROmvm4nIPj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Repayment and interest accretion">(413,236</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance at June 30, 2021</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_986_eus-gaap--OperatingLeaseLiability_iI_pp0p0_c20210630__us-gaap--AdjustmentsForNewAccountingPronouncementsAxis__us-gaap--AccountingStandardsUpdate201902Member_zwhp305zTmdk" style="border-bottom: Black 2.5pt double; text-align: right" title="Operating lease obligation">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Current portion of operating lease obligation</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pp0p0_c20210630__us-gaap--AdjustmentsForNewAccountingPronouncementsAxis__us-gaap--AccountingStandardsUpdate201902Member_zr0kR7DUrFxa" style="text-align: right" title="Current portion of operating lease obligation">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Noncurrent portion of operating lease obligation</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0_c20210630__us-gaap--AdjustmentsForNewAccountingPronouncementsAxis__us-gaap--AccountingStandardsUpdate201902Member_ztcbcVbTYkYk" style="text-align: right" title="Noncurrent portion of operating lease obligation">-</td><td style="text-align: left"> </td></tr> </table> The operating lease expense was $67,607 for the three months ended June 30, 2021, and was included in the general and administrative expenses. During June 2021, the Company entered into a short-term lease for the leased premise at monthly base rent of $19,177. The extended term is not to extend beyond Dec 31, 2021.

0.10

<p id="xdx_895_eus-gaap--OperatingLeasesOfLesseeDisclosureTextBlock_zAqU7mdNVK91" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"> SCHEDULE OF OPERATING LEASES OBLIGATIONS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">$</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">Operating lease right-of-use asset - initial recognition</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_980_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0_c20210331__us-gaap--AdjustmentsForNewAccountingPronouncementsAxis__us-gaap--AccountingStandardsUpdate201902Member_zZ7U9OYYKbc7" style="width: 16%; text-align: right" title="Operating lease right-of-use asset - initial recognition">413,236</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Amortization</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--OperatingLeaseRightOfUseAssetAmortizationExpense_pp0p0_c20210401__20210630__us-gaap--AdjustmentsForNewAccountingPronouncementsAxis__us-gaap--AccountingStandardsUpdate201902Member_zminqs4JABng" style="border-bottom: Black 1.5pt solid; text-align: right" title="Amortization">(413,236</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance at June 30, 2021</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0_c20210630__us-gaap--AdjustmentsForNewAccountingPronouncementsAxis__us-gaap--AccountingStandardsUpdate201902Member_ziVzK594moEj" style="border-bottom: Black 2.5pt double; text-align: right" title="Operating lease right-of-use asset">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Operating lease obligation - initial recognition</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--OperatingLeaseLiability_iI_pp0p0_c20210331__us-gaap--AdjustmentsForNewAccountingPronouncementsAxis__us-gaap--AccountingStandardsUpdate201902Member_zDNFgvki0A3g" style="text-align: right" title="Operating lease obligation - initial recognition">413,236</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Repayment and interest accretion</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_ecustom--OperatingLeaseRepaymentAndInterestAccretion_pp0p0_c20210401__20210630__us-gaap--AdjustmentsForNewAccountingPronouncementsAxis__us-gaap--AccountingStandardsUpdate201902Member_zrROmvm4nIPj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Repayment and interest accretion">(413,236</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance at June 30, 2021</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_986_eus-gaap--OperatingLeaseLiability_iI_pp0p0_c20210630__us-gaap--AdjustmentsForNewAccountingPronouncementsAxis__us-gaap--AccountingStandardsUpdate201902Member_zwhp305zTmdk" style="border-bottom: Black 2.5pt double; text-align: right" title="Operating lease obligation">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Current portion of operating lease obligation</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pp0p0_c20210630__us-gaap--AdjustmentsForNewAccountingPronouncementsAxis__us-gaap--AccountingStandardsUpdate201902Member_zr0kR7DUrFxa" style="text-align: right" title="Current portion of operating lease obligation">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Noncurrent portion of operating lease obligation</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0_c20210630__us-gaap--AdjustmentsForNewAccountingPronouncementsAxis__us-gaap--AccountingStandardsUpdate201902Member_ztcbcVbTYkYk" style="text-align: right" title="Noncurrent portion of operating lease obligation">-</td><td style="text-align: left"> </td></tr> </table>

413236

-413236

413236

-413236

67607

19177

The extended term is not to extend beyond Dec 31, 2021.

<p id="xdx_80D_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zwrfzVHo0wU3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">10. CONTINGENCIES There are no unrecognized claims against the company that were assessed as significant, which were outstanding as at June 30, 2021 and, consequently, no additional provision for such has been recognized in the consolidated financial statements during the three and nine months then ended.

11. SUBSEQUENT EVENTS The Company’s management has evaluated subsequent events up to August 16, 2021, the date the condensed consolidated financial statements were issued, pursuant to the requirements of ASC 855 and has determined the following material subsequent events: On July 2, 2021, the Company issued <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210701__20210702__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zt7mRnoNCZj8" title="Number of preferred shares issued">100 preferred shares to an existing preferred shareholder for proceeds of $<span id="xdx_90C_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_c20210701__20210702__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zpnjvv7KrH3a" title="Proceeds from preferred stock issued">100,000. During the period from July 1 to August 16, the Company received conversion notices to convert $<span id="xdx_909_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20210701__20210816__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zEd8urgu8Uke" title="Debt instrument, convertible amount">5,268,000 in convertibles notes, together with $428,000 in accrued interest, into common shares. Pursuant to receipt of these conversion notices, the Company has processed the issuance of <span id="xdx_905_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20210701__20210702__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zEiYSJIZkEDg" title="Debt instrument, convertible shares">2,273,400 common shares. During this same period, has issued <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20210701__20210702__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--InvestorsMember_zXqueAQPWBi1" title="Number of shares issued for convertible notes">59,883 common shares to investors in the respective convertible notes who have exercised warrants issued in prior periods. Also during this same period, the Company issued <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20210701__20210702__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--BrokersMember_z2NTMvyr87J3" title="Number of shares issued for convertible notes">36,060 common shares to brokers who exercised placement agent warrants received as compensation.

100

100000

5268000

428000

2273400

59883

36060